Vaccine

Published by Butterworth-Heinemann Ltd

Index to volume 10 (1992)

No 1 pp 1–72
No 2 pp 73–136
No 3 pp 173–200
No 4 pp 201–296
No 5 pp 297–360
No 6 pp 363–424
No 7 pp 425–488
No 8 pp 489–560
No 9 pp 561–640
No 10 pp 641–728
No 11 pp 729–808
No 12 pp 809–888
No 13 pp 889–968
No 14 pp 969–1080
Supplement 1 pp S1–S176

Author Index

Aarhaug, P.
Field evaluation of a hepatitis A vaccine in a Norwegian contingent to the United Nations Interim Force in Lebanon, S156
Aaronson, W. *see* Dragunsky, E.M., 735
Abraham, E.
Intranasal immunization with bacterial polysaccharide containing liposome enhances antigen-specific pulmonary secretory antibody response, 461
Adler, B. *see* McGillivery, D.J., 607
Adu, F.D. *see* Onoja, A.L., 49
Agundis, C. *see* Garcia-Sainz, J.A., 341
Ahsan, C.R. *see* Ciznar, J., 591
Aizawa, C. *see* Gizurarson, S., 101
Akoglu, E. *see* Soyletir, G., 301
Al-Bokmy, A.M. *see* Hafez, S.M., 533
Al-Mukayel, A. *see* Hafez, S.M., 533
Al-Sukayran, S. *see* Hafez, S.M., 533
Alter, M.J. *see* Shapiro, C.N., S59
Amador, R. *see* Patarroyo, G., 175
Amador, R., Moreno, A., Valero, V., Murillo, L., Mora, A.L., Rojas, M., Rocha, C., Salcedo, M., Guzman, F. and Espejo, F.
The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity, 179
Ambrosch, F. *see* Wiedermann, G., S129
Ambrosch, F., Andre, F.E., Delem, A., D'Hondt, E., Jonas, S., Kunz, C., Safary, A. and Wiedermann, G.
Simultaneous vaccination against hepatitis A and B: results of a controlled study, S142
Amjad, A.M. *see* Hafez, S.M., 533
Anderson, C. *see* Rossi-Campos, A., 512
Anderson, R.M.
The concept of herd immunity and the design of community-based immunization programmes, 928
Andre, F. *see* Goubau, P., 114
Andre, F. *see* Jilg, W., S126
Andre, F.E. *see* Wiedermann, G., S129
Andre, F.E. *see* Ambrosch, F., S142
Andre, F.E., D'Hondt, E., Delem, A. and Safary, A.
Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings, 160
Andrews, M.E., Boyle, D.B., Coupar, B.E.H., Reddy, D., Bellamy, A.R. and Both, G.W.
Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea, 185
Aparisi, L. *see* Rodrigo, J.M., 798
Apau, N. *see* Blumberg, D.A., 614
Arnon, R. *see* Seta, M., 991
Arnon, R. *see* McEwen, J., 405
Arrand, J.R. *see* Madej, M., 777
Artero, A. *see* Rodrigo, J.M., 798
Artois, M., Guittre, C., Thomas, I., Leblois, H., Brochier, B. and Barrat, J.
Potential pathogenicity for rodent of vaccines intended for oral vaccination against rabies: a comparison, 524
Aubertin, A.M. *see* Le Grand, R., 873
Auerbach, B.S., Wilson, M.E., Lake, A.M., Deforest, A., Steinhoff, M. and Halsey, N.A.
Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15–24 months and 4–6 years of age, 14
Aurelian, L. *see* Wachsman, M., 447
Avraham, R. *see* Samina, I., 217
Azuma, I. *see* Ishihara, C., 353
Azuma, I. *see* Yoo, Y.C., 792
Azuma, I.
Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity, 1000
Baba, K. *see* Tanaka, K., 824
Babiuk, L.A. *see* Hughes, H.P.A., 226
Babiuk, L.A. *see* Frenchick, P.J., 783
Baer, G.M. *see* Follmann, E.H., 305
Bahceci, E. *see* Soyletir, G., 301
Baig, M.A. *see* Chinnah, A.D., 551
Baker, L.R. *see* Blumberg, D.A., 614
Balayan, M.S. *see* Elbert, L.B., 828
Balayan, M.S.
Natural hosts of hepatitis A virus, S27
Banatvala, J.E. *see* Tilzey, A.J., S121
Bancroft, W. *see* Hoke, C.K., S75
Bancroft, W. *see* Sjogren, M.H., S135
Bankova, V. *see* Dimov, V., 817
Barbuti, S. *see* Squarcione, S., 853
Barrat, J. *see* Artois, M., 524
Barreto, L. *see* Scheifele, D., 455
Barrett, A.D.T. *see* Sil, B.K., 329
Barrett, A.D.T. *see* Ledger, T.N., 652
Barrett, A.D.T. *see* Wills, M.R., 861
Barrett, T. *see* Visser, I.K.G., 435
Barrow, S. *see* Tilzey, A.J., S121
Bartkova, G. *see* Ciznar, J., 591
Bartoloni, S. *see* Rappuoli, R., 1027
Baudrihaye, N.
European vaccine manufacturers: present status and future trends, 893
Baxby, D. and Paoletti, E.
Potential use of non-replicating vectors as recombinant vaccines, 8
Beaudoin, late R.L. *see* Sedegah, M., 578
Beesley, J.E. *see* Bomford, R., 572
Begg, N.T. *see* Porter, J.D.H., 334
Bellamy, A.R. *see* Andrews, M.E., 185
Belshe, R.B. *see* Gorse, G.J., 383
Ben-Ahmeida, E.T.S. *see* Gregoriadis, G., 747

0264-410X/92/141061-19
© 1992 Butterworth-Heinemann Ltd

Ben-Chetrit, E. *see* Schattner, A., 98
Benaissa-Trouw, B.J. *see* Boots, A.M.H., 119
Bennett, D.D. *see* Wright, S.E., 375
Bergamini, F. *see* Squarcione, S., 853
Berger, R. and Just, M.
Vaccination against hepatitis A: Control 3 years after the first vaccination, 295
Berger, R. and Just, M.
Vaccination against hepatitis A: Control 3 years after the first vaccination, 295
Berger, R. *see* Just, M., 110
Berger, R. *see* Just, M., 737
Berthold, H. *see* Hofmann, F., S82
Bhatnaghar, P.K. *see* Dillon, S.B., 309
Bienzle, C. *see* Muller, R., S124
Billstrom, M.A. *see* Skinner, G.R.B., 847
Binn, L. *see* Sjogren, M.H., S135
Binn, L. *see* Purcell, R.H., S148
Binn, L.N. *see* Hoke, Jr, C.H., S75
Binn, L.N., MacArthy, P.O., Marchwicki, R.H., Sjogren, M.H., Hoke, Jr, C.H., Burge, J.R. and D'Hondt, E.
Laboratory tests and reference reagents employed in studies of inactivated hapatitis A vaccine, S102
Bittner, R. *see* Jilg, W., S126
Bjornson, G. *see* Scheifele, D., 455
Blondeau, C. *see* Coursaget, P., 379
Blumberg, D.A., Chatfield, P.C., Cherry, J.D., Robinson, R.G., Smith, K., Mabie, L., Holroyd, H.J., Baker, L.R., Dudenhoeffer, late F.E. and Apau, N.
Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine, 614
Booerts, H. *see* Muller, R., S124
Bock, H. *see* Muller, R., S124
Bock, H. *see* Harabacz, I., 145
Bock, H.L. *see* Jilg, W., S126
Bock, H.L. *see* Theilmann, L., 132
Bock, H.L. *see* Kallinowski, B., 500
Bolognesi, D.P. *see* Karzon, D.T., 1039
Bomford, R., Stapleton, M., Winsor, S., Beesley, J.E., Jessup, E.A., Price, K.R. and Fenwick, G.R.
Adjuvanticity and ISCOM formation by structurally diverse saponins, 572
Bonneau, A.-M. *see* Ewasyshyn, M., 412
Boots, A.M.H., Benaissa-Trouw, B.J., Hesselink, W., Rijke, E., Schrier, C. and Hensen, E.J.
Induction of anti-viral immune responses by immunization with recombinant-DNA encoded avian coronavirus nucleocapsid protein, 119
Bosanquet, N. *see* Leese, B., 491
Bositis, C.M. *see* Lu, S., 3
Boselgo, J. W. *see* Innis, B.L., S159
Both, G.W. *see* Andrews, M.E., 185
Bourdil, C. *see* Coursaget, P., 319
Bourdil, C. *see* Coursaget, P., 379
Boyle, D.B. *see* Andrews, M.E., 185
Bradbury, R. *see* Purcell, R.H., S148
Brantschen, S. *see* Just, M., 737
Brault, S. *see* Trudel, M., 107
Brenner, J. *see* Samina, I., 217
Briggs, D.J. and Schwenke, J.R.
Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine, 125
Bringer, L. *see* Coursaget, P., 379
Brizard, A. *see* Coursaget, P., 319
Brochier, B. *see* Artois, M., 524
Brown, E.A. *see* Lemon, S.M., S40
Brown, F., 1022
New approaches to vaccination against foot-and-mouth disease, 1022
Browning, M., Reid, G., Osborne, R. and Jarrett, O.
Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies, 585
Brulein, V. *see* Leentvaar-Kuijpers, A., S138
Bryan, J.P., Sjogren, M.H., Macarthy, P., Cox, E., Legters, L.J. and Perine, P.L.
Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose, 33
Buchan, A. *see* Skinner, G.R.B., 847
Burge, J. R. *see* Binn, L.N., S102
Burke, R.L. *see* Ho, R.J.Y., 209

Campos, M. *see* Hughes, H.P.A., 226
Cantell, K. *see* Pyhala, R., 631
Cao, J.X. *see* Sil, B.K., 329
Cao, J.X. *see* Wills, M.R., 861
Cao, M., Sasaki, O., Yamada, A. and Imanishi, J.
Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines, 238
Capelli, M. *see* Degrassi, A., 617
Caplan, B. *see* Ewasyshyn, M., 412
Carrillo, C. *see* Gonzalez, M., 731
Casal, J.I. *see* Martinez, C., 684
Caudill, J. *see* Sjogren, M.H., S135
Cellesi, C. *see* Sansoni, A., 627
Chan, S.H. *see* Yap, I., 439
Chanock, R.M. *see* Connors, M., 475
Chantra, A. *see* Suntharasamai, P., 502
Chapsal, J.-M. *see* Vaux-Peretz, F., 113
Charles, I. *see* Chatfield, S.N., 53
Charles, I.G. *see* Roberts, M., 43
Chatfield, P.C. *see* Blumberg, D.A., 614
Chatfield, S.N., Fairweather, N., Charles, I., Pickard, D., Levine, M., Hone, D., Posada, M., Strugnell, R.A., Dougan, G.
Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine, 53
Cherian, T. *see* Samuel, B.U., 135
Cherian, T. *see* Samuel, B.U., 74
Cherry, J.D. *see* Blumberg, D.A., 614
Cherry, J.D.
Pertussis: the trials and tribulations of old and new pertussis vaccines, 1033
Chesebro, B. *see* Ishihara, C., 353
Chiang, C.H. *see* Sedegah, M., 578
Chinnah, A.D., Baig, M.A. and Tizard, I.R.
Antigen dependent adjuvant activity of a polydispersed β-(1,4)-linked acetylated mannan (acemannan), 551
Chiron, J.P. *see* Coursaget, P., 379
Chriske, H. *see* Muller, R., S124
Ciardelli, T. *see* Lu, S., 3
Ciznar, J., Ahsan, C.R., Rahman, A. Shahabuddin, M., Bartkova, G., Clemens, J.D. and Sack, D.A.
Crossed immunoelectrophoretic analysis of antigenic composition of B-subunit/whole-cell and whole-cell only killed oral cholera vaccines, 591
Clegg, J.C.S.
Current progress towards vaccines for arenavirus-caused diseases, 89
Clemens, J. *see* Holmgren, J., 146
Clemens, J.D. *see* Ciznar, J., 591
Clemens, R. *see* Jilg, W., S126
Clemens, R. *see* Muller, R., S124
Clemens, R. *see* Kallinowski, B., 500
Cochran, M. *see* Herrington, D.A., 841
Cochran, M.D. *see* Sedegah, M., 578
Colemann, P.J. *see* Shapiro, C.N., S59
Collins, P.L. *see* Connors, M., 475
Collins, Wm.E. *see* Millet, P., 547
Connors, M., Collins, P.L., Firestone, C.-Y., Sotnikov, A.V., Waitze, A., Davis, A.R., Hung, P.P., Chanock, R.M., Murphy, B.R.
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV re, 475
Conway, M.J. *see* Madej, M., 777
Cooper, G.L., Venables, L.M., Nicholas, R.A.J., Cullen, G.A. and Hormaeche, C.E.
Vaccination of chickens with chicken-derived Salmonella enteritidis phage type 4 oroA live oral salmonella vaccines, 247
Corbel, M.J. *see* Porter, J.D.H., 334
Cortes, E. *see* Martinez, C., 684
Costantino, P. *see* Sansoni, A., 627
Costantino, P., Viti, S., Podda, A., Velmonte, M.A., Nencioni, L. and Rappouli, R.
Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C, 691
Coupar, B.E.H. *see* Andrews, M.E., 185
Coursaget, P., Relyveld, E., Brizard, A., Frenkiel, M.P., Fritzell, B., Teulieres, L., Bourdil, C., Yvonnet, B., Jeannee, E. and Guindo, S.
Simultaneous injection of hepatitis B vaccine with BCG and killed poliovirus vaccine, 319
Coursaget, P., Bringer, L., Sarr, G., Bourdil, C., Fritzell, B., Blondeau, C., Yvonnet, B., Chrion, J.P., Jeannee, E. and Guindo, S.
Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine, 379
Coutinho, R.S. *see* Leentvaar-Kuijpers, A., S138
Covacci, A. *see* Rappuoli, R., 1027
Cox, E. *see* Bryan, J.P., 33
Cramm, M. *see* Van Damme, P., 366
Cullen, G.A. *see* Cooper, G.L., 247
Cumins, L.B. *see* Rupprecht, C.E., 368

D'Hondt, E. *see* Hoke, Jr, C.H., S75
D'Hondt, E. *see* Binn, L.N., S102
D'Hondt, E. *see* Goubau, P., S114
D'Hondt, E. *see* Wiedermann, G., S129
D'Hondt, E. *see* Ambrosch, F., S142
D'Hondt, E. *see* Purcell, R.H., S148

D'Hondt, E. *see* Andre, F.E., S160
D'Hondt, E.
New approaches for hepatitis A vaccines, S48
Dalrymple, J.M. *see* Schmaljohn, C.S., 10
Dalsgaard, K. *see* Martinez, C., 684
Davidson, M., Krugman, S. and Sandman, L.A.
Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals, S119
Davies, J. *see* Skinner, G.R.B., 847
Davis, A.R. *see* Connors, M., 475
Davis, A.R. *see* Tacket, C.O., 673
DeFraites, R.F. *see* Hoke, Jr, C.H., S75
Deforest, A. *see* Auerbach, B.S., 14
Degrassi, A., Mariani, E., Honorati, M.C., Roda, P., Miniero, R., Capelli, M. and Facchini, A.
Cellular response anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine, 617
Deinhardt, F. *see* Muller, R., S124
Deinhardt, F. *see* Jilg, W., S126
Deinhardt, F.
Prevention of viral hepatitis A: past, present and future, S10
Dejonghe, P. and Parkinson, B.
Benefits and costs of vaccination, 936
dela Cruz, D. *see* Hafez, S.M., 533
del Canho, R., Schalm, S.W. and Heijtink, R.A.
Hepatitis B revaccination of neonates with inadequate response after primovaccination, 69
del Olmo, J.A. *see* Rodrigo, J.M., 798
Delem, A. *see* Goubau, P., 114
Delem, A. *see* Wiedermann, G., S129
Delem, A. *see* Ambrosch, F., S142
Delem, A. *see* Andre, F.E., S160
de Magistris, M.T. *see* Rappuoli, R.
Demuth, S.G. see Dillon, S.B., 309
Denchev, V. *see* Mitov, I., 61
Dertzbaugh, M.T. *see* McGhee, J.R., 75
Desmyter, J. *see* Goubau, P., 114
de Turiso, J.A.L. *see* Martinez, C., 684
Dietrich, M. *see* Muller, R., S124
Dierich, M. P. *see* Most, J., 740
Dietzschold, B. *see* Schumacher, C.L., 754
Dillon, S.B., Demuth, S.G., Schneider, M.A., Weston, C.B., Jones, C.S., Young, J.F., Scott, M., Bhatnaghar, P.K., LoCastro, S. and Hanna, N.
Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant, 309
Dimov, V., Ivanovska, N., Bankova, V. and Popov, S.
Immunomodulatory action of propolis: IV. Prophylactic activity against Gram-negative infections and adjuvant effect of the water-soluble derivative, 817
Ditommaso, S. *see* Zotti, C., 742
Dolgaya, T.M. *see* Dragunsky, E.M., 735
Dong, D.-X. *see* Xu, Z.-Y., S67
Dormont, D. *see* Le Grand, R., 873
Dougan, G. *see* Roberts, M., 43
Dougan, G. *see* Chatfield, S.N., 53
Dragunsky, E.M., Rivera, E., Aaronson, W., Dolgaya, T.M., Hochstein, H.D., Habig, Wm.H. and Levenbook, I.S.
Experimental evaluation of antitoxic protective effect of new cholera vaccines in mice, 735
Drechsler, H. *see* Just, M., 737
Dubois, D. *see* Hoke, Jr, C.H., S75
Dudenhoeffer, late F.E. *see* Blumberg, D.A., 614
Dunster, L.M. *see* Ledger, T.N., 652

Ebenbichler, C.F. *see* Most, J., 740
Eckel, K.H. *see* Hoke, Jr, C.H., S75
Edelman, R. *see* Tacket, C.O., 673
Edelman, R. *see* Herrington, D.A., 841
Egan, J.E. *see* Hoke, Jr, C.H., S75
Ehrenfeld, E. *see* Robertson, B.H., 106
Ekstrom, J. *see* Fekadu, M., 192
Elbert, L.B., Lisitzina, E.A., Kusov, Y.Y. and Balayan, M.S.
Immunogenicity of inactivated purified tissue culture vaccine against hepatitis A (HepAvac) assessed in laboratory rodents, 828
Eldridge, J.H. *see* McGhee, J.R., 75
Elfaki, M.G., Kleven, S.H., Jin, L.H. and Ragland, W.L.
Sequential intracoelomic and intrabursal immunization of chickens with inactivated Mycoplasma gallisepticum bacterin and iota carrageenan adjuvant, 655
Emerson, S.U. *see* Purcell, R.H., S148
Emerson, S.U., Huang, Y.K., McRill, C., Lewis, M., Shapiro, M., London, Wm.T. and Purcell, R.H.
Molecular basis of virulence and growth of hepatitis A virus in cell culture, S36
Emili, A. *see* Phillips, N.C., 151
Enders, B., Hundt, E. and Knapp, B.
Strategies on the development of an antimalarial vaccine, 920
Erasmus, B.J. *see* Roy, P., 28
Ertl, H.C.J. *see* Schumacher, C.L., 754
Escudero, A. *see* Rodrigo, J.M., 798
Esdaile, J. *see* Lifely, M.R., 159
Esparza, I. and Kissel, T.
Parameters affecting the immunogenicity of microencapsulated tetanus toxoid, 714
Espejo, F. *see* Amador, R., 179
Ewasyshyn, M., Caplan, N., Bonneau, A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M.
Comparative analysis of the immuno-stimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine, 412

Facchini, A. *see* Degrassi, A., 617
Fairweather, N. *see* Chatfield, S.N., 53
Fairweather, N.F. *see* Roberts, M., 43
Fanti, O. *see* Sansoni, A., 627
Farrington, C.P. *see* Porter, J.D.H., 334
Fatunmbi, O.O., Newman, J.A., Sivanandan, V. and Halvorson, D.A.
Enhancement of antibody response of turkeys to trivalent avian influenza vaccine by positively charged liposomal avridine adjuvant, 623
Feinstone, S. *see* Sjogren, M.H., S135
Fekadu, M., Shaddock, J.H., Ekstrom, J., Oterhaus, A., Sanderlin, D.W., Sundquist, B. and Morein, B.
An immune simulating complex (ISCOM) subunit rabies vaccine protects dogs and mice against street rabies challenge, 192
Fenwick, G.R. *see* Bomford, R., 572
Ferenczi, E. *see* Holzmann, H., 345
Firestone, C.-Y. *see* Connors, M., 475
Follmann, E.H., Ritter, D.G. and Baer, G.M.
Oral rabies vaccination of arctic foxes (Alopex lagopus) with an attenuated vaccine, 305
Formal, S.B. *see* Newland, J.W., 766
Forrest, B.D.
Effects of sample processing on the measurement of specific intestinal IgA immune responses, 802
Forsum, U. *see* Li, A., 395
Franco, L. *see* Patarroyo, G., 175
Fraser, M.J. *see* McLinden, J.H., 231
French, T. *see* Roy, P., 28
Frenchick, P.J., Sabara, M.I.J., Ready, K.F.M. and Babiuk, L.A.
Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles, 783
Frenkiel, M.P. *see* Coursaget, P., 319
Frey, S.E. *see* Gorse, G.J., 383
Fritzell, B. *see* Coursaget, P., 319
Fritzell, B. *see* Coursaget, P., 379
Fritzell, C., Rollin, P.E., Touir, M., Sureau, P. and Teulieres, L.
Safety and immunogenicity of combined rabies and typhoid fever immunization, 299
Frosner, G.G. *see* Riedemann, S., S152
Fujiyama, S. *see* Iino, S., 323
Funnell, S.G.P. *see* Robinson, A., 139
Furminger, I.,
Introduction: Vaccines for the world, 892

Garcia, F. *see* Rodrigo, J.M., 798
Garcia, J.A. *see* Isibasi, A., 811
Garcia-Sainz, J.A., Romero-Avila, M.T., Ruiz-Arriaga, A., Ruiz-Puente, J., Agundis, C., Ortoz, V. and Isibasi, A.
Characterization and detoxification of an easily prepared acellular pertussis vaccine. Antigenic role of the A protomer of pertussis toxin, 341
Gerlach, G.-F. *see* Rossi-Campos, A., 512
Germinario, C. *see* Squarcione, S., 853
Gibson, C.A. *see* Sil, B.K., 329
Gilabert, M.S. *see* Rodrigo, J.M., 798
Gizurarson, S., Tamura, S., Aizawa, C. and Kurata, T.
Stimulation of the transepithelial flux of influenza HA vaccine by cholera toxin B subunit, 101
Gluck, R. *see* Just, M., 737
Gluck, R.
Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens, 915
Gmelin, K. *see* Theilmann, L., 132
Gmelin, K. *see* Kallinowski, B., 500
Godson, D. *see* Hughes, H.P.A., 226
Goldschmidt, T.G. *see* Lu, S., 3
Gonzalez, C.R. *see* Isibasi, A., 811
Gonzalez, J.L. *see* Riedemann, S., S152
Gonzalez, M., Mateu, M.G., Martinez, M.A., Carrillo, C. and Sobrino, F.
Comparison of capsid protein VP1 of the viruses used for the production and challenge of foot-and-mouth disease

vaccines in Spain, 731
Gonzalez, R. *see* Rodrigo, J.M., 798
Gordon, D.M. *see* Herrington, D.A., 841
Gorse, G.J., Belshe, R.B., Newman, F.K., Frey, S.E. and Vaccine Clinical Trials Network NIAID AIDS
Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160, 383
Goubau, P., Van Gerven, V., Safary, A., Delem, A., Knops, J., D'Hondt, E., Andre, F. and Desmyter, J.
Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine, 114
Govindarajan, S. *see* Purcell, R.H., S148
Graham, S. *see* Ewasyshyn, M., 412
Greco, D. *see* Squarcione, S., 853
Gregoriadis, G., Tan, L., Ben-Ahmeida, E.T.S. and Jennings, R.
Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen, 747
Groothuis, J.R., Levin, M.J., Lehr, M.V., Weston, J.A. and Hayward, A.R.
Immune response to split-product influenza vaccine in preterm and full-term young children, 221
Guan, R. *see* Yap, I., 439
Guasparini, R. *see* Scheifele, D., 455
Guindo, S. *see* Coursaget, P., 319
Guindo, S. *see* Coursaget, P., 379
Guittre, C. *see* Artois, M., 524
Gupta, C.K. *see* Sokhey, J., 423
Gupta, R.K. *see* Sokhey, J., 423
Gurvich, E.B.
The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine, 96
Gust, I.D.
Epidemiological patterns of hepatitis A in different parts of the world, S56
Gust, I.D.,
How an outbreak of hepatitis A in Melbourne led to the development of a vaccine, S9
Guzman, F. *see* Amador, R., 179
Habig, Wm.H. *see* Dragunsky, E.M., 735
Hafez, S.M., Al-Sukayran, A., dela Cruz, D., Mazloum, K.S., Al-Bokmy, A.M., Al-Mukayel, A. and Amjad, A.M.
Development of a live cell culture camelpox vaccine, 533

Hale, T.L. *see* Newland, J.W., 766
Halsey, N.A. *see* Auerbach, B.S., 14
Halvorson, D.A. *see* Fatunmbi, O.O., 623
Hang, C.-S. *see* Song, G., 214
Hanlon, C.A. *see* Rupprecht, C.E., 368
Hanna, N. *see* Dillon, S.B., 309
Hao, Fu-Y. *see* Song, G., 214
Harabacz, I., Bock, H., Jungst, Ch., Klochmann, U., Praus, M. and Weber, R.
A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens, 145
Hardy, L. *see* Lu, S., 3
Hasty, S.E. *see* Schmaljohn, C.S., 10
Hayward, A.R. *see* Groothuis, J.R., 221
Heath, A.W. and Playfair, J.H.L.
Cytokines as immunological adjuvants, 427
Heijtink, R.A. *see* del Canho, R., 69
Heinz, F.X. *see* Holzmann, H., 345
Hensen, E.J. *see* Boots, A.M.H., 119
Hering, V. *see* Riedemann, S., S152
Herrington, D.A., Losonsky, G.A., Smith, G., Volvovitz, F., Cochran, M., Jackson, K., Hoffman, S.L., Gordon, D.M., Levine, M.M. and Edelman, R.
Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells, 841
Hesla, P.E.
Hepatitis A in Norwegian troops, S80
Hess, G. *see* Muller, R., S124
Hesselink, W. *see* Boots, A.M.H., 119
Hilleman, M.R.
Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS, 1053
Hingley, P.J. *see* Pay, T.W.F., 699
Hingley, P.J. *see* Pay, T.W.F., 707
Hirasawa, M. *see* McGhee, J.R., 75
Ho, R.J.Y., Burke, R.L. and Merigan, T.C.
Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs, 209
Hochstein, H.D. *see* Dragunsky, E.M., 735
Hoffman, S.L. *see* Sedegah, M., 578
Hoffman, S.L. *see* Herrington, D.A., 841
Hofmann, F. *see* Muller, R., S124
Hofmann, F. *see* Theilmann, L., S132
Hofmann, F. *see* Kallinowski, B., 500
Hofmann, F., Wehrle, G., Berthold, H. and Koster, D.
Hepatitis A as an occupational hazard, S82
Hoke, Jr, C.H. *see* Binn, L.N., S102
Hoke, C. *see* Sjogren, M.H., S135
Hoke, Jr, C.H., Binn, L.N., Egan, J.E., DeFraites, R.F., MacArthy, P.O., Innis, B.L., Eckel, K.H., Dubois, D., D'Hondt, E. and Sjogren, M.H.
Hepatitis A in the US Army: epidemiology and vaccine development, S75
Holmgren, J. *see* Jertborn, M., 130
Holmgren, J., Svennerholm, A.-M., Jertborn, M., Clemens, J., Sack, D.A., Salensted, R. and Wigzell, H.
An oral B subunit: whole cell vaccine against cholera, 146
Holroyd, H.J. *see* Blumberg, D.A., 614
Holzmann, H., Vorobyova, M.S., Ladyzhenskaya, I.P., Ferenzci, E., Kundi, M., Kunz, C. and Heinz, F.X.
Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes, 345
Honda, T. *see* Kaji, M., 663
Hone, D. *see* Chatfield, S.N., 53
Honorati, M.C. *see* Degrassi, A., 617
Hopf, U. *see* Muller, R., S124
Horiuchi, K. *see* Iino, S., 323
Hormaeche, C.E. *see* Cooper, G.L., 247
Horn, S.D. *see* Nathanson, N., 469
Horwith, G. *see* Tacket, C.O., 673
Horwitz, R.J. *see* McEwen, J., 405
Houghten, R.A. *see* Sedegah, M., 578
Hu, Y.X. *see* Wills, M.R., 861
Huang, Y.-C. *see* Song, G., 214
Huang, Y.K. *see* Emerson, S.U., S36
Huei, L.-J. *see* Song, G., 214
Huemer, H.P. *see* Most, J., 740
Hughes, H.P.A., Campos, M., van Drunen Littel-van den Hurk S., Zamb, T., Sordillo, L.M., Godson, D. and Babiuk, L.A.
Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV, 226
Humphreys, R.E. *see* Lu, S., 3
Hundt, E. *see* Enders, B., 920
Hung, P. *see* Tacket, C.O., 673
Hung, P.P. *see* Connors, M., 475
Hunter, R.L. *see* Millet, P., 547
Huo, Z.-W. *see* Song, G., 214

Iandolo, E. *see* Squarcione, S., 853
Ibarra, H. *see* Riedemann, S., S152
Iino, S., Fujiyama, S., Horiuchi, K., Jyo, K., Kuwabara, Y., Sato, S., Saika, S., Morita, M., Odoh, K. and Kuzuhara, S.
Clinical trial of a lyophilized inactivated hepatitis A candidate vaccine in healthy adult volunteers, 323
Ikuta, K. *see* Nishino, Y., 677
Imanishi, J. *see* Cao, M., 238
Innis, B.L. *see* Hoke, Jr, C.H., S75
Innis, B.L., Snitbhan, R., Kunasol, P., Laorakpongse, T., Poopatanakool, W., Suntayakorn, S., Suknantapong, T., Safary, A., Boslego, J.W.
Field efficacy trial of inactivated hepatitis A vaccine among children in Thailand (an extended abstract), S159
Ishihara, C., Miyazawa, M., Nishio, J., Azuma, I. and Chesebro, B.
Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukaemia retrovirus-induced disease, 353
Isibasi, A. *see* Garcia-Sainz, J.A., 341
Isibasi, A., Ortiz-Navarrete, V., Paniagua, J., Pelayo, R., Gonzalez, C.R., Garcia, J.A. and Kumate, J.
Active protection of mice against Salmonella typhi by immunization with strain-specific porins, 811
Islam, M.A. *see* Sil, B.K., 329
Ivanovska, N. *see* Dimov, V., 817

Jackson, K. *see* Herrington, D.A., 841
Jansen, R.W. *see* Lemon, S.M., S40
Jarrett, O. *see* Browning, M., 585
Jeannee, E. *see* Coursaget, P., 319
Jeannee, E. *see* Coursaget, P., 379
Jennings, A.D. *see* Sil, B.K., 329
Jennings, R. *see* Gregoriadis, G., 747
Jertborn, M. *see* Holmgren, J., 146
Jertborn, M., Svennerholm, A.-M. and Holmgren, J.
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers, 130
Jessup, E.A. *see* Bomford, R., 572
Jia, X.-Y. *see* Robertson, B.H., 106
Jilg, J. *see* Muller, R., S124
Jilg, W., Bittner, R., Bock, H.L., Clemens, R., Schatzl, H., Schmidt, M., Andre, F. and Deinhardt, F.

Vaccination against hepatitis A: comparison of different short-term immunization schedules, S126
Jin, L.H. *see* Elfaki, M.G., 655
Johansson, B.E. and Kilbourne, E.D.
Influenza vaccine strain selection: equivalence of two antigenically distinct haemagglutinin variants of 1989 H3N2 influenza A virus in protection of mice, 603
John, T.J. *see* Samuel, B.U., 74
John, T.J. *see* Samuel, B.U., 135
John, T.J., Nambiar, A., Samuel, B.U. and Rajasingh, J.
Ulnar nerve inoculation of poliovirus in bonnet monkey: a new primate model to investigate neurovirulence, 529
Jonas, S. *see* Ambrosch, F., S142
Jones, C.S. *see* Dillon, S.B., 309
Jungst, Ch. *see* Harabacz, I., 145
Just, M. and Berger, R.
Reactogenicity and immunogenicity of inactivated hepatitis A vaccines 110
Just, M. *see* Berger, R., 295
Just, M., Berger, R., Drechsler, H., Brantschen, S. and Gluck, R.
A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks, 737
Jyo, K. *see* Iino, S., 323

K-Sakai, H. *see* Oh, Y., 506
Kahler, W. *see* von Hedenstrom, M., 949
Kaji, M., Kaji, Y., Kaji, M., Ohkuma, K., Honda, T., Oka, T., Sakoh, M., Nakamura, S., Kurachi, K. and Sentoku, M.
Phase 1 clinical tests of influenza MDP-virosome vaccine (KD-5382), 663
Kaji, Y. *see* Kaji, M., 663
Kalish, M.L. *see* Millet, P., 547
Kallinowski, B. *see* Theilmann, L., 132
Kallinowski, B., Gmelin, K., Kommerell, B., Bock, H.L., Clemens, R., Scheiermann, N., Wohland, B., Hofmann, F., Theilmann, L.
Immunogenicity, reactogenicity and consistency of a new, inactivated hepatitis A vaccine – a randomized multicentre study with three consecutive vaccine lots, 500
Kane, M.A.
Perpsective on the control of hepatitis A by vaccination, S93
Karnell, A., Sweiha, H. and Lindberg, A.A.
Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes, 167
Karnell, A., Stocker, B.A.D., Katakura, S., Reinholt, F.P. and Lindberg, A.A.
Live oral auxotrophic Shigella flexneri SFL124 vaccine with a deleted aroD gene: Characterization and monkey protection studies, 389
Karzon, D.T., Bolognesi, D.P. and Koff, W.C.
Development of a vaccine for the prevention of AIDS, a critical appraisal, 1039
Katakura, S. *see* Karnell, A., 389
Kaul, S. *see* Kumar, A., 814
Khanna, R. *see* Vinayak, V.K., 21
Khuller, M. *see* Vinayak, V.K., 21
Kilbourne, E.D. *see* Johansson, B.E., 603
Kim, R. *see* Oh, Y., 506
Kim-Farley, R.J.
EPI for the 1990s, 940
Kimman, T.G.
Comparative efficacy of three doses of the genetically engineered Aujeszky's disease virus vaccine strain 783 in pigs with maternal antibodies, 363
Kimura, M. *see* Oh, Y., 506
Kimura, T. *see* Nishino, Y., 677
Kissel, T. *see* Esparza, I., 714
Kiyono, H. *see* McGhee, J.R., 75
Klashinsky, S. *see* Rossi-Campos, A., 512
Kleemola, M. *see* Pyhala, R., 631
Klein, M. *see* Ewasyshyn, M., 412
Kleven, S.H. *see* Elfaki, M.G., 655
Klockmann, U. *see* Harabacz, I., 145
Knapp, B. *see* Enders, B., 920
Knops, J. *see* Goubau, P., 114
Koff, R.S.
Clinical manifestation and diagnosis of hepatitis A virus infection, S15
Koff, W.C. *see* Karzon, D.T., 103
Kommerell, B. *see* Kallinowski, B., 500
Koprowski, H. *see* Rupprecht, C.E., 368
Koprowski, H. *see* Schumacher, C.L., 754
Koster, D. *see* Hofmann, F., S82
Krugman, S. *see* Davidson, M., S119
Kum, K. *see* Vinayak, V.K., 21
Kumar, A., Kaul, S., Manivel, V. and Rao, K.V.S.
Comparison of immune responses to a native viral antigen and a synthetic peptide derived from it: implications for vaccine development, 814
Kumate, J. *see* Isibasi, A., 811
Kumpulainen, V. *see* Pyhala, R., 631
Kunasol, P. *see* Innis, B.L., S159
Kundi, M. *see* Holzmann, H., 345
Kunz, C. *see* Ambrosch, F., S142
Kunz, C. *see* Holzmann, H., 345
Kurachi, K. *see* Kaji, M., 663
Kurata, T. *see* Gizurarson, S., 101
Kusov, Y.Y. *see* Elbert, L.B., 828
Kuwabara, Y. *see* Iino, S., 323
Kuzuhara, S. *see* Iino, S., 323

Ladyzhenskaya, I.P. *see* Holzmann, H., 345
Lake, A.M. *see* Auerbach, B.S., 14
Lam, V. *see* Lu, S., 3
Laorakpongse, T. *see* Innis, B.L., S159
Lappi, S. *see* Pyhala, R., 631
Larcher, C. *see* Most, J., 740
Lawrance, R.A. *see* Soyletir, G., 301
Le Grand, R., Vogt, G., Vaslin, B. Roques, P., Theodoro, F., Aubertin, A.M. and Dormont, D.
Specific and non-specific immunity and protection of macaques against SIV infection, 873
Leblois, H. *see* Artois, M., 524
Ledger, T.N., Sil, B.K., Dunster, L.M., Stephenson, J.R., Minor, P.D. and Barrett, A.D.T.
Yellow fever 17DD vaccine virus is temperature sensitive when grown in mosquito C6-36 cells, 652
Leentvaar-Kuijpers, A., Coutinho, R.A., Brulein, V. and Safary, A.
Simultaneous passive and active immunization against hepatitis A, S138
Leese, B. and Bosanquet, N.
Immunization in the UK: policy review and future economic options, 491
Legters, L.J. *see* Bryan, J.P., 33
Lehr, M.V. *see* Groothuis, J.R., 221
Lemieux, S. *see* Trudel, M., 107
Lemon, S.M., Jansen, R.W. and Brown, E.A.
Genetic, antigenic and biological differences between strains of hepatitis A virus, S40
Leon, J. *see* Riedemann, S., S152
Levenbook, I.S. *see* Dragunsky, E.M., 735
Levi, R. *see* McEwen, J., 405
Levin, M.J. *see* Groothuis, J.R., 221
Levine, M. *see* Chatfield, S.N., 53
Levine, M.M. *see* Tacket, C.O., 673
Levine, M.M. *see* Herrington, D.A., 841
Lew, R.A. *see* Lu, S., 3
Lewis, M. *see* Emerson, S.U., S36
Li, A., Pal, T., Forsum, U. and Lindberg, A.A.
Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers, 395
Li, De-X. *see* Song, G., 214
Li, S.-L. *see* Song, G., 214
Li, Z.-H. *see* Xu, Z.-Y., S67
Lifely, M.R., Rogers, M.V., Esdaile, J., Payne, M. and Tite, J.P.
Murine cross-reactive T-cell epitopes of Neisseria meningitidis outer membrane proteins, 159
Lindberg, A.A. *see* Karnell, A., 167
Lindberg, A.A. *see* Karnell, A., 389
Lindberg, A.A. *see* Li, A., 395
Linde, K. *see* Mitov, I., 61
Lisitzina, E.A. *see* Elbert, L.B., 828
Liu, W.-M. *see* Song, G., 214
Lo Caputo, S. *see* Squarcione, S., 853
LoCastro, S. *see* Dillon, S.B., 309
London, Wm.T. *see* Emerson, S.U., S36
Losonsky, G. *see* Tacket, C.O., 673
Losonsky, G.A. *see* Herrington, D.A., 841
Lu, S., Reyes, V.E., Bositis, C.M., Goldschmidt, T.G., Lam, V., Torgerson, R.R., Ciardelli, T., Hardy, L., Lew, R.A. and Humphreys, R.E.
Biophysical mechanism of the scavenger site near T cell-presented epitopes, 3
Lubeck, M.S. *see* Tacket, C.O., 673
Lugosi, L. and Molnar, I.
Biostatistical manual (BIOSTAT) for potency control and for evaluation of effectiveness of the WHO-EPI vaccines: software for personal computers, 157
Luo, J.H. *see* Wachsman, M., 447
Lusignan, Y. *see* Trudel, M., 107

Mabie, L. *see* Blumberg, D.A., 614
MacArthy, P.O. *see* Hoke, Jr, C.H., S75
MacArthy, P.O. *see* Binn, K.N., S102
Macarthy, P. *see* Bryan, J.P., 33
Macarthy, P. *see* Sjogren, M.H., S135
Mackett, M. *see* Madej, M., 777
Madej, M., Conway, M.J., Morgan, A.J., Sweet, J., Wallace, L., Qualtiere, L.F., Arrand, J.R. and Mackett, M.
Purification and characterization of Epstein-Barr virus gp340/220 produced by a

bovine papillomavirus virus expression vector system, 777
Magrath, D.I.
Availability of vaccines of an assured quality, 952
Maiwald, H. *see* Muller, R., S124
Maiwald, H. *see* Theilmann, L., S132
Malinoski, F.J.
Strenuous exercise simulating hepatic injury during vaccine trials, 43
Manivel, V. *see* Rao, K.V.S., 204
Manivel, V. *see* Kumar, A., 814
Manning, P.A.
Molecular design of cholera vaccines, 1015
Marchwicki, R.H. *see* Binn, L.N., S102
Margolis, H.S. and Shapiro, C.N.
Who should receive hepatitis A vaccine? Considerations for the development of an immunization strategy, S85
Margolis, H.S. *see* Shapiro, C.N., S59
Margolis, H.S. *see* Robertson, B.H., 106
Mariani, E. *see* Degrassi, A., 617
Martinez, C., Dalsgaard, K., de Turiso, J.A.L., Cortes, E., Vela, C. and Casal, J.I.
Production of porcine parvovirus empty capsids with high immunogenic activity, 684
Martinez, M.A. *see* Gonzalez, M., 731
Massironi, E. *see* Zuin, G., 857
Mateu, M.G. *see* Gonzalez, M., 731
May, B. *see* Muller, R., S124
Mazloum, K.S. *see* Hafez, S.M., 533
McEwen, J., Levi, R., Horwitz, R.J. and Arnon, R.
Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice, 405
McGhee, J.R., Mestecky, J., Dertzbaugh, M.T., Eldridge, J.H., Hirasawa, M. and Kiyono, H.
The mucosal immune system: from fundamental concepts to vaccine development, 75
McGillivery, D.J., Yong, W.K., Adler, B. and Riffkin, G.G.
A purified stage-specific 31 kDa antigen as a potential protective antigen against Ostertagia circumcincta infection in lambs, 607
McKee, K. *see* Sjogren, M.H., S135
McLinden, J.H., Ploplis, V.A., Fraser, M.J. and Rosen, E.D.
Expression of foreign epitopes on recombinant occlusion bodies of baculoviruses, 231
McQuillan, G.M. *see* Shapiro, C.N., S59
McRill, C. *see* Emerson, S.U., S36
Meekison, Wm. *see* Scheifele, D., 455
Meheus, A. *see* Van Damme, P., 366
Meignier, B. *see* Vaux-Peretz, F., 113
Mellouk, S. *see* Sedegah, M., 578
Melnick, J.L.
Properties and classification of hepatitis A virus, S24
Merigan, T.C. *see* Ho, R.J.Y., 209
Mestecky, J. *see* McGhee, J.T., 75
Migasena, S. *see* Suntharasamai, P., 502
Mikami, T. *see* Nishino, Y., 677
Millet, P., Kalish, M.L., Collins, Wm.E. and Hunter, R.L.
Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malaria peptide vaccine, 547
Miniero, R. *see* Degrassi, A., 617
Minor, P.D. *see* Ledger, T.N., 652
Mitov, I., Denchev, V. and Linde, K.
Humoral and cell-mediated immunity in mice after immunization with live oral vaccines of Salmonella typhimurium: auxotrophic mutants with two attenuating markers, 61
Miyazawa, M. *see* Ishihara, C., 353
Mizutani, S. *see* Tacket, C.O., 673
Molnar, I. *see* Lugosi, L., 157
Mora, A.L. *see* Amador, R., 179
Moraleda, L. *see* Riedemann, S., S152
Morein, B. *see* Fekadu, M., 192
Moreno, A. *see* Amador, R., 179
Morgan, A.J. *see* Madej, M., 777
Morgan, A.J.
Epstein–Barr virus vaccines, 563
Moriabadi, F.K. *see* Theilmann, L., 132
Morikawa, S. *see* Nishino, Y., 677
Morita, M. *see* Iino, S., 323
Most, J., Larcher, C., Vogetseder, W., Prodinger, W.M., Huemer, H.P., Ebenbichler, C.F. and Dierich, M.P.
Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students, 740
Muller, R., Chriske, H., Deinhardt, F., Jilg, J., Theilmann, L., Hess, G., Hofmann, F., Hopf, U., Stickl, H. and Maiwald, H.
Hepatitis A vaccination: schedule for accelerated immunization, S124
Muotiala, A.
Anti-IFN-γ-treated mice – a model for testing safety of live Salmonella vaccines, 243
Murillo, L. *see* Amador, R., 179
Murillo, L.A. *see* Patarroyo, G., 175
Murphy, B.R. *see* Connors, M., 475

Nadon, F. *see* Trudel, M., 107
Nakamura, S. *see* Kaji, M., 663
Naksrisook, S. *see* Suntharasamai, P., 502
Nambiar, A. *see* John, T.J., 529
Nathanson, N. and Horn, S.D.
Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964–1988, 469
Nencioni, L. *see* Rappuoli, R., 1027
Nencioni, L. *see* Costantino, P., 691
Newland, J.W., Hale, T.L. and Formal, S.B.
Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12–Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen, 766
Newman, F.K. *see* Gorse, G.J., 383
Newman, J.A. *see* Fatunmbi, O.O., 623
Nicholas, R.A.J. *see* Cooper, G.L., 247
Nishino, Y., Ohki, K., Kimura, T., Morikawa, S., Mikami, T. and Ikuta, K.
Major core proteins, p24s, of human, simian, and feline immunodeficiency viruses are partly expressed on the surface of the virus-infected cells, 677
Nishio, J. *see* Ishihara, C., 353
Nordenfelt, E.
Hepatitis A in Swedish travellers, S73
O'Grady, J.
Management of acute and fulminant hepatitis A, S21

Odoh, K. *see* Iino, S., 323
Oh, Y., Ohta, K., K-Sakai, H., Kim, R. and Kimura, M.
Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine, 506
Ohki, K. *see* Nishino, Y., 677
Ohkuma, K. *see* Kaji, M., 663
Ohta, K. *see* Oh, Y., 506
Oka, T. *see* Kaji, M., 663
Oktada, S. *see* Tanaka, K., 824
Okuno, T. *see* Tanaka, K., 824
Olin, P. *see* Storsaeter, J., 142
Onoja, A.L., Adu, F.D. and Tomori, O.
Evaluation of measles vaccination programme conducted in two separate health centres, 49
Ortiz, V. *see* Garcia-Sainz, J.A., 341
Ortiz-Navarrete, V. *see* Isibasi, A., 811
Orvell, C. *see* Visser, I.K.G., 435
Osborne, R. *see* Browning, M., 585
Osterhaus, A. *see* Fekadu, M., 192
Osterhaus, A.D.M.E. *see* Visser, I.K.G., 435

Paccagnini, S. *see* Zuin, G., 857
Pal, T. *see* Li, A., 395
Palmer, S.J. *see* Tilzey, A.J., S121
Panda, S.K. *see* Rao, K.V.S., 204
Paniagua, J. *see* Isibasi, A., 811
Paoletti, E. *see* Baxby, D., 8
Paoletti, E. *see* Wachsman, M., 447
Papaevangelou, G.
Epidemiology of hepatitis A in Mediterranean countries, S63
Parkinson, B. *see* Dejonghe, P., 936
Patarroyo, G., Franco, L., Amador, R., Murillo, L.A., Rocha, C.L., Rojas, M. and Patarroyo, M.E.
Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1–14 years, 175
Patarroyo, M.E. *see* Patarroyo, G.,, 175
Pay, T.W.F. and Hingley, P.J.
Foot and mouth disease vaccine potency tests in cattle: the interrelationship of antigen dose, serum neutralizing antibody response and protection from challenge, 699
Pay, T.W.F. and Hingley, P.J.
A potency test method for foot and mouth disease vaccine based on the serum neutralizing antibody response produced in cattle, 707
Payne, M. *see* Lifely, M.R., 159
Peetermans, J.
Production, quality control and characterization of an inactivated hepatitis A vaccine, S99
Peeters, C.C.A.M., Tenbergen-Meekes, A.-M.J., Poolman, J.T., Zegers, B.J.M. and Rijkers, G.T.
Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high doses of free saccharide, 833
Pelayo, R. *see* Isibasi, A., 811
Peleg, B.-A. *see* Samina, I., 217

Perine, P.L. *see* Bryan, J.P., 33
Perkin, M.A. *see* Porter, J.D.H., 334
Perry, K.R. *see* Tilzey, A.J., S121
Phillips, N.C. and Emili, A.
Enhanced antibody response to liposome-associated protein antigens: preferential stimulation of IgG2a/b production, 151
Pickard, D. *see* Chatfield, S.N., 53
Pierce, N.
Editorial: Vaccines for enteric diseases,, 203
Pitisuttitham, P. *see* Suntharasamai, P., 502
Pizza, M. *see* Rappouli, R., 1027
Playfair, J.H.L. *see* Heath, A.W., 427
Ploplis, V.A. *see* McLinden, J.H., 231
Podda, A. *see* Rappuoli, R., 1027
Podda, A. *see* Costantino, P., 691
Ponka, A. *see* Pyhala, R., 631
Poolman, J.T. *see* Peeters, C.C.A.M., 833
Poopatanakool, W. *see* Innis, B.L., S159
Poore, P.
Availability of quality vaccines: policies of a non-government organization, 958
Popov, S. *see* Dimov, V., 817
Porter, J.D.H., Perkin, M.A., Corbel, M.J., Farrington, C.P., Watkins, J.T. and Begg, N.T.
Lack of early antitoxin response to tetanus booster, 334
Posada, M. *see* Chatfield, S.N., 53
Potter, A.A. *see* Rossi-Campos, A., 512
Praus, M. *see* Harabacz, I., 145
Price, K.R. *see* Bomford, R., 572
Principi, N. *see* Zuin, G., 857
Prodinger, W.M. *see* Most, J., 740
Profeta, M.L. *see* Squarcione, S., 853
Purcell, R.H. *see* Emerson, S.U., S36
Purcell, R.H. *see* Sjogren, M.H., S135
Purcell, R.H., D'Hondt, E., Bradbury, R., Emerson, S.U., Govindarajan, S. and Binn, L.
Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees, S148
Pyhala, R., Kleemola, M., Kumpulainen, V., Vartiainen, E., Lappi, S., Ponka, A. and Cantell, K. *Immune response to inactivated influenza B viruses of two highly distinct evolutionary lineages*, 631

Qualtiere, L.F. *see* Madej, M., 777
Quarto, M. *see* Squarcione, S., 853

Raghupathy, P. *see* Samuel, B.U., 74
Raghupathy, P. *see* Samuel, B.U., 135
Ragland, W.L. *see* Elfaki, M.G., 655
Ragni, M.C. *see* Zuin, G., 857
Rahman, A. *see* Ciznar, J., 591
Rajasingh, J. *see* Samuel, B.U., 74
Rajasingh, J. *see* Samuel, B.U., 135
Rajasingh, J. *see* John, T.J., 529
Rao, D.N. *see* Ritu, G., 761
Rao, K.V.S. *see* Kumar, A., 814
Rao, K.V.S., Panda, S.K. and Manivel, V.
Macromolecular self-association of a synthetic peptide derived from the hepatitis B surface antigen: construction of a quaternary epitope, 204
Rappouli, R. *see* Sansoni, A., 627
Rappouli, R. *see* Costantino, P., 691
Rappouli, R., Podda, A., Pizza, M., Covacci, A., Bartoloni, A., de Magistris, M.T. and Nencioni, L.
Progress towards the development of new vaccines against whooping cough, 1027
Re, M. see Zuin, G., 857
Ready, K.F.M. *see* Frenchick, P.J., 783
Reddy, D. *see* Andrews, M.E., 185
Reddy, G.S. and Srinivasan, V.A.
Use of BHK cell culture-adapted Newcastle virus for immunization of chicks, 164
Reese, R.T. *see* Sharma, P., 540
Reid, G. *see* Browning, M., 585
Reid, G.
Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid, 597
Reinhardt, G. *see* Riedemann, S., S152
Reinholt, F.P. *see* Karnell, A., 389
Relyveld, E. *see* Coursaget, P., 319
Reyes, V.E. *see* Lu, S., 3
Richman, S.J. *see* Sharma, P., 540
Riedemann, S., Reinhardt, G., Frosner, G.G., Ibarra, H., Moraleda, L., Hering, V., Siegel, F., Toledo, C., Leon, J. and Gonzalez, J.L.
Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile, S152
Riffkin, G.G. *see* McGillivery, D.J., 607
Rijke, E. *see* Boots, A.M.H., 119
Rijkers, G.T. *see* Peeters, C.C.A.M., 833
Ritter, D.G. *see* Follmann, E.H., 305
Ritu, G. and Rao, D.N.
Construction of synthetic immunogens: Use of T- and B-cell epitopes of CS and RESA proteins of Plasmodium falciparum, 761
Rivera, E. *see* Dragunsky, E.M., 735
Roberts, Jr, N.J. *see* Salkind, A.R., 519
Roberts, M., Tite, J.P., Fairweather, N.F., Dougan, G. and Charles, I.G.
Recombinant P.69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection, 43
Robertson, B.H., Jia, X.-Y., Tian, H., Margolis, H.S., Summers, D. F. and Ehrenfeld, E.
Serological approaches to distinguish immune response to hepatitis A vaccine and natural infection, 106
Robinson, A. and Funnell, S.G.P.
Potency testing of acellular pertussis vaccines, 139
Robinson, R.G. *see* Blumberg, D.A., 614
Rocha, C. *see* Amador, R., 179
Rocha, C.L. *see* Patarroyo, G., 175
Roda, P. *see* Degrassi, A., 617
Rodrigo, J.M., Serra, M.A., Aparisi, L., Escudero, A., Gilabert, M.S., Garcia, F., Gonzalez, R., del Olmo, J.A., Wassel, A.H. and Artero, A.
Immune response to hepatitis B vaccine in parenteral drug abusers, 798
Rogers, M.V. *see* Lifely, M.R., 159
Rojas, M. *see* Patarroyo, G., 175
Rojas, M. *see* Amador, R., 179
Rollin, P.E. *see* Fritzell, C., 299
Romero-Avila, M.T. *see* Garcia-Sainz, J.A., 341
Roques, P. *see* Le Grand, R., 873
Rosen, E.D. *see* McLinden, J.H., 231
Rossi-Campos, A., Anderson, C., Gerlach, G.-F., Klashinsky, S., Potter, A.A. and Wilson, P.J.
Immunization of pigs against Actinobacillus pleuropneumoniae with two recombinant protein preparations, 512
Roy, P., French, T. and Erasmus, B.J.
Protective efficacy of virus-like particles for bluetongue disease, 28
Ruggenini, A.M. *see* Zotti, C., 742
Ruiz-Arriaga, A. *see* Garcia-Sainz, J.A., 341
Ruiz-Puente, J. *see* Garcia-Sainz, J.A., 341
Rupprecht, C.E., Hanlon, C.A., Cummins, L.B. and Koprowski, H.
Primate responses to a vaccinia–rabies glycoprotein recombinant virus vaccine, 368
Russo, R. *see* Zotti, C., 742

Sabara, M.I.J. *see* Frenchick, P.J., 783
Sack, D.A. *see* Holmgren, J., 146
Sack, D.A. *see* Ciznar, J., 591
Sadoff, J.C. *see* Hoke, C.H., S75
Safary, A. *see* Goubau, P., 114
Safary, A. *see* Tilzey, A.J., S121
Safary, A. *see* Wiedermann, G., S129
Safary, A. *see* Leentvaar-Kuijpers, A., S138
Safary, A. *see* Ambrosch, F., S142
Safary, A. *see* Innis, B.L., S159
Safary, A. *see* Andre, F.E., S160
Safary, A. *see* Van Damme, P., 366
Saika, S. *see* Iino, S., 323
Saiki, I. *see* Yoo, Y.C., 792
Sakoh, M. *see* Kaji, M., 663
Salcedo, M. *see* Amador, R., 179
Salensted, R. *see* Holmgren, J., 146
Salkind, A.R. and Roberts, Jr, N.J.
Recent observations regarding the pathogenesis of recurrent respiratory syncytial virus infections: implications for vaccine development, 519
Samina, I., Brenner, J., Avraham, R. and Peleg, B.-A.
Enhancement of the immune response by intradermal vaccination in cattle with enterotoxigenic Escherichia coli (ETEC) vaccine without adjuvant, 217
Samuel, B.U. *see* John, T.J., 529
Samuel, B.U., Cherian, T., Rajasingh, J., Raghupathy, P. and John, T.J.
Immune response of infants to inactivated poliovirus vaccine injected intradermally, 74
Samuel, B.U., Cherian, T., Rajasingh, J., Raghupathy, P. and John, T.J.
Immune response of infants to inactivated poliovirus vaccine injected intradermally, 135
Sanderlin, D.W. *see* Fekadu, M., 192
Sandman, L.A. *see* Davidson, M., S119
Sansoni, A., Rappouli, R., Viti, S., Costantino, P., Fanti, O. and Cellesi, C.
Immunity to Haemophilus influenzae type b on sample population from central Italy, 627
Sarr, G. *see* Coursaget, P., 379
Sasaki, O. *see* Cao, M., 238
Sato, K. *see* Yoo, Y.C., 792
Sato, S. *see* Iino, S., 323
Schalm, S.W. *see* del Canho, R., 69
Schattner, A., Ben-Chetrit, E. and

Schmilovitz, H.
Poliovaccines and the course of systemic lupus erythematosus – a retrospective study of 73 patients, 98
Schatzl, H. *see* Jilg, W., S126
Schatzmayr, H.G.
The countries' point of view, 954
Scheiermann, N. *see* Theilmann, L., 132
Scheiermann, N. *see* Kallinowski, B., 500
Scheifele, D., Bjornson, G., Barreto, L., Meekison, Wm. and Guasparini, R.
Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh, 455
Schiff, E.R.
Atypical clinical manifestations of hepatitis A, S18
Schmaljohn, C.S., Hasty, S.E. and Dalrymple, J.M.
Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome, 10
Schmidt, M. *see* Jilg, W., S126
Schmilovitz, H. *see* Schattner, A., 98
Schofeld, C. *see* Muller, R., S124
Schneider, M.A. *see* Dillon, S.B., 309
Schrier, C. *see* Boots, A.M.H., 119
Schumacher, C.L., Ertl, H.C.J., Koprowski, H. and Dietzschold, B.
Inhibition of immune responses against rabies virus by monoclonal antibodies directed against rabies virus antigens, 754
Schwenke, J.R. *see* Briggs, D.J., 125
Scollard, N. *see* Ewasyshyn, M., 412
Scott, M. *see* Dillon, S.B., 309
Sedegah, M., Chiang, C.H., Weiss, W.R., Mellouk, S., Cochran, M.D., Houghten, R.A., Beaudoin, late R.L., Smith, D., Hoffman, S.L.
Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity, 578
See, A. *see* Sjogren, M.H., S135
Seguin, C. *see* Trudel, M., 107
Sentoku, M. *see* Kaji, M., 663
Serra, M. A. *see* Rodrigo, J.M., 798
Seta, M. and Arnon, R.
Synthetic approaches to vaccines for infectious and autoimmune diseases, 991
Shaddock, J.H. *see* Fekaru, M., 192
Shahabuddin, M. *see* Ciznar, J., 591
Shapiro, C.N. *see* Margolis, H.S., S85
Shapiro, C.N., Colemann, P.J., McQuillan, G.M., Alter, M.J. and Margolis, H.S.
Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA, S59
Shapiro, M. *see* Emerson, S.U., S36
Sharda, R. *see* Sil, B.K., 329
Sharma, B. *see* Sokhey, J., 423
Sharma, P., Richman, S.J. and Reese, R.T.
Antibody responses stimulated in rabbits, guinea-pigs and mice by recombinant and synthetic portions of a 75 kDa malarial merozoite protein, 540
Siegel, F. *see* Riedemann, S., S152
Siegl, G.
Replication of hepatitis A virus and processing of proteins, S32
Sil, B.K. *see* Ledger, T.N., 652
Sil, B.K. *see* Wills, M.R., 861
Sil, B.K., Wills, M.R., Cao, J.X., Sharda, R., Islam, M.A., Stagg, D.J., Jennings, A.D., Gibson, C.A. and Barrett, A.D.T.
Immunogenicity of experimental live attenuated Japanese encephalitis vaccine viruses and comparison with wild-type strains using monoclonal and polyclonal antibodies, 329
Silvaplana, P. *see* Zotti, C., 742
Sivandan, V. *see* Fatunmbi, O.O., 623
Sjogren, M.H. *see* Bryan, J.P., 33
Sjogren, M.H. *see* Hoke, Jr, C.H., 75
Sjogren, M.H. *see* Binn, L.N., S102
Sjogren, M.H., Purcell, R.H., McKee, K., Binn, L., Macarthy, P., Ticehurst, J., Feinstone, S., Caudill, J., See, A. and Hoke, C.
Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate, S135
Skinner, G.R.B., Davies, J., Billstrom, M.A. and Buchan, A.
In vivo model for evaluation of species-specific virus vaccines, 847
Smith, D. *see* Sedegah, M., 578
Smith, G. *see* Herrington, D.A., 841
Smith, K. *see* Blumberg, D.A., 614
Snitbhan, R. *see* Innis, B.L., S159
Sobrino, F. *see* Gonzalez, M., 731
Sokhey, J., Gupta, C.K., Sharma, B. and Gupta, R.K.
Statistical evaluation of virus titres of working standard of oral polio vaccine, 423
Song, G., Huang, Y.-C., Hang, C.-S., Hao, Fu.-Y., Li, De-X., Zheng, X.-L., Liu, W.-M., Li, S.-L., Huo, Z.-W. and Huei, L.-J.
Preliminary human trial of inactivated gold hamster kidney cell (GHKC) vaccine against haemorrhagic fever with renal syndrome (HFRS), 214
Sordillo, L.M. *see* Hughes, H.P.A., 226
Sotnikov, A.V. *see* Connors, M., 475
Soyletir, G., Bahceci, E., Akoglu, E., Soyogul, U. and Lawrance, R.A.
Clinical evaluation of low dose intradermally administered hepatitis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines, 301
Soyogul, U. *see* Soyletir, G., 301
Spier, R.E.
Editorial: Getting their act together, 891
Spier, R.E.
Editorial: Prophylaxis: the foundation for our future progress, 971
Squarcione, S., Germinario, C., Iandolo, E., Lo Caputo, S., Bergamini, F., Profeta, M.L., Greco, D., Quarto, M., Barbuti, S.
Seroimmunity to poliomyelitis in an Albanian immigrant population, 853
Srinivasan, V.A. *see* Reddy, G.S., 164
Stagg, D.J. *see* Sil, B.K., 329
Stapleton, J.T.
Passive immunization against hepatitis A S45
Stapleton, M. *see* Bomford, R., 572
Steffen, R.
Risk of hepatitis A in travellers, S69
Steinhoff, M. *see* Auerbach, B.S., 14
Stephenne, J.
Contribution to hepatitis B prevention, 900
Stephenson, J.R. *see* Ledger, T.N., 652
Stickl, H. *see* Muller, R., 124
Stickl, H. *see* Theilmann, L., S132
Stocker, B.A.D. *see* Karnell, A., 389
Storsaeter, J. and Olin, P.
Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance, 142
Strugnell, R.A. *see* Chatfield, S.N., 53
Suknantapong, T. *see* Innis, B.L., S159
Summers, D.F. *see* Robertson, B.H., 106
Sundquist, B. *see* Fekadu, M., 192
Suntayakorn, S. *see* Innis, B.L., 159
Suntharasamai, P., Migasena, S., Vongsthongsri, U., Supanaranond, W., Pitisuttitham, P., Supeeranan, L., Chantra, A. and Naksrisook, S.
Clinical and bacteriological studies of El Tor cholera after ingestion of known inocula in Thai volunteers, 502
Supanaranond, W. *see* Suntharasamai, P., 502
Supeeranan, L. *see* Suntharasamai, P., 502
Sureau, P. *see* Fritzell, C., 299
Sureau, P.
Contribution to rabies prevention, 896
Svennerholm, A.-M. *see* Jertborn, M., 130
Svennerholm, A.-M. *see* Holmgren, J., 146
Swartz, T.A.
Preventive strategies against poliomyelitis, 904
Sweet, J. *see* Madej, M., 777
Sweiha, H. *see* Karnell, A., 167

Tacket, C.O., Losonsky, G., Lubeck, M.D., Davis, A.R., Mizutani, S., Horwith, G., Hung, P., Edelman, R., Levine, M.M.
Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine, 673
Takahashi, M. *see* Tanaka, K., 824
Takahashi, M.
Current status and prospects of live varicella vaccine, 1007
Tamura, S. *see* Gizurarson, S., 101
Tan, L. *see* Gregoriadis, G., 747
Tanaka, K., Baba, K., Oktada, S., Okuno, Y., Yamanishi, K., Ueda, S., Takahashi, M. and Yamada, A.
Nasal antibody response to mumps virus after vaccination and natural infection, 824
Tenbergen-Meekes, A.-M.J. *see* Peeters, C.C.A.M., 833
Teulieres, L. *see* Fritzell, C., 299
Teulieres, L. *see* Coursaget, P., 319
Theilmann, L. *see* Muller, R., S124
Theilmann, L. *see* Kallinowski, B., 500
Theilmann, L., Kallinowski, B., Gmelin, K., Hofmann, F., Scheiermann, N., Wohland, B., Stickl, H., Maiwald, H., Moriabadi, F.K. and Bock, H.L.
Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine, S132
Theodoro, F. *see* Le Grand, R., 873
Thomas, I. *see* Artois, M., 524
Tian, H. *see* Robertson, B.H., 106

Ticehurst, J. *see* Sjogren, M.H., S135
Tilzey, A.J., Palmer, S.J., Barrow, S., Perry, K.R., Tyrell, H., Safary, A. and Banatavala, J.E.
Effect of hepatitis A vaccination schedules on immune response, S121
Tite, J.P. *see* Roberts, M., 43
Tite, J.P. *see* Lifely, M.R.,, 159
Tizard, I.R. *see* Chinnah, A.D., 551
Toledo, C. *see* Riedemann, S., S152
Tomori, O. *see* Onoja, A.L., 49
Torgerson, R.R. *see* Lu, S., 3
Tormans, G., Van Damme, P. and Van Doorslaer, E.
Cost-effectiveness analysis of hepatitis A prevention in travellers, S88
Tornaghi, R. *see* Zuin, G., 857
Touir, M. *see* Fritzell, C., 299
Trudel, M., Nadon, F., Seguin, C., Brault, S., Lusignan, Y. and Lemieux, S.
Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine, 107
Tyrell, H. *see* Tilzey, A.J., S121

Ueda, S. *see* Tanaka, K., 824
Usman, S. *see* Ewasyshyn, M., 412

Vaccine Clinical Trials Network NIAID AIDS *see* Gorse, G.J., 383
Valero, V. *see* Amador, R., 179
Van Damme, P. *see* Tormans, G., S88
Van Damme, P., Cramm, M., Safary, A., Vandepapeliere, P. and Meheus, A.
Heat stability of a recombinant DNA hepatitis B vaccine, 366
van de Bildt, M.W.G. *see* Visser, I.K.G., 435
van Drunen Littel-van den Hurk, S. *see* Hughes, H.P.A., 226
Van Doorslaer, E. *see* Tormans, G., S88
Van Gerven, V. *see* Goubau, P., 114
Vandepapeliere, P. *see* Van Damme, P., 366
Vandersmissen, W.
Availability of quality vaccines: The industrial point of view, 955
van Noort, R.B.J.C.
The Children's Vaccine Initiative and vaccine supply, 909
Vartiainen, E. *see* Pyhala, R., 631
Vaslin, B. *see* Le Grand, R., 873
Vaux-Peretz, F., Chapsal, J.-M. and Meignier, B.
Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice, 113
Vedder, E.J. *see* Visser, I.K.G., 435
Vela, C. *see* Martinez, C., 684
Velmonte, M.A. *see* Costantino, P., 691
Venables, L.M. *see* Cooper, G.L., 247
Vinayak, V.K., Kum, K., Khanna, R. and Khuller, M.
Systemic-oral immunization with 56 kDa molecule of Giardia lamblia affords protection in experimental mice, 21
Visser, I.K.G., Vedder, E.J., van de Bildt, M.W.G., Orvell, C., Barrett, T. and Osterhaus, A.D.M.E.
Canine distemper virus ISCOMs induce protection in harbour seals (Phoca vitulina) against phocid distemper but still allow subsequent infection with phocid distemper virus-1, 435
Viti, S. *see* Sansoni, A., 627
Viti, S. *see* Costantino, P., 691
Vogetseder, W. *see* Most, J., 740
Vogt, G. *see* Le Grand, R., 873
von Hedenstrom, M. and Kahler, W.
The cold chain from manufacturer to vaccinator: experiments and experiences, 949
Volvovitz, F. *see* Herrington, D.A., 841
Vongsthongsri, U. *see* Suntharasamai, P., 502
Vorobyova, M.S. *see* Holzmann, H., 345

Wachsman, M., Luo, J.H., Aurelian, L. and Paoletti, E.
Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D, 447
Waitze, A. *see* Connors, M., 475
Walker, P.D.
Bacterial vaccines: old and new, veterinary and medical, 977
Wallace, L. *see* Madej, M., 777
Wang, J.-X. *see* Xu, Z.-Y., S67
Wardlaw, A.C.
Multiple discontinuity as a remarkable feature of the development of acellular pertussis vaccines, 643
Wassel, A.H. *see* Rodrigo, J.M., 798
Watkins, J.T. *see* Porter, J.D.H., 334
Watson, D.L.
Staphylococcal mastitis vaccine, 359
Weber, R. *see* Harabacz, I., 145
Wehrle, G. *see* Hofmann, F., S82
Weiss, W.R. *see* Sedegah, M., 578
Weston, C.B. *see* Dillon, S.B., 309
Weston, J.A. *see* Groothuis, J.R., 221
Wiedermann, G. *see* Ambrosch, F., S142
Wiedermann, G., Ambrosch, F., Andre, F.E., D'Hondt, E., Delem, A. and Safary, A.
Persistence of vaccine-induced antibody to hepatitis A virus, S129
Wigzell, H. *see* Holmgren, J., 146
Wills, M.R. *see* Sil, B.K., 329
Wills, M.R., Sil, B.K., Cao, J.X., Hu, Y.X. and Barrett, A.D.T.
Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area, 861
Wilson, M.E. *see* Auerbach, B.S., 14
Wilson, P.J. *see* Rossi-Campos, A., 512
Winsor, S. *see* Bomford, R., 572
Wohland, B. *see* Theilmann, L., 132
Wohland, B. *see* Kallinowski, B., 500
Wright, S.E. and Bennett, D.D.
Avian retroviral recombinant expressing foreign envelope delays tumour formation of ASV-A-induced sarcoma, 375

Xiao, Z.-P. *see* Xu, Z.-Y., S67
Xu, Z.-Y., Li, Z.-H., Wang, J.-X., Xiao, Z.-P. and Dong, D.-X.
Ecology and prevention of a shellfish-associated hepatitis A epidemic in Shanghai, China, S67

Yamada, A. *see* Cao, M., 238
Yamada, A. *see* Tanaka, K., 824
Yamanishi, K. *see* Tanaka, K., 824
Yap, I., Guan, R. and Chan, S.H.
Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein – a preliminary study on immunogenicity, 439
Yong, W.K. *see* McGillivery, D.J., 607
Yoo, Y.C., Saiki, I., Sato, K. and Azuma, I.
B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and anti-metastatic effect in mice, 792
Young, J.F. *see* Dillon, S.B., 309
Yvonnet, B. *see* Coursaget, P., 319
Yvonnet, B. *see* Coursaget, P., 379

Zamb, T. *see* Hughes, H.P.A., 226
Zegers, B.J.M. *see* Peeters, C.C.A.M., 833
Zheng, X.-L. *see* Song, G., 214
Zimmerman, H. *see* Muller, R., S124
Zotti, C., Silvaplana, P., Ditommaso, S., Russo, R. and Ruggenini, A.M.
Compulsory and non-compulsory immunizations: contraindications perceived by medical practitioners, 742
Zuin, G., Principi, N., Tornaghi, R., Paccagnini, S., Re, M., Massironi, E. and Ragni, M.C.
Impaired response to hepatitis B vaccine in HIV infected children, 857

Subject Index

A protomer
Pertussis, Acellular, 341
AIDS
Pathogenesis, Dedicated research team, 1053
HIV, Vaccine development, 1039
AIDS animal model
SIV vaccine, 873
Acellular
Pertussis, A protomer, 341
Acellular pertussis vaccine
Potency testing, Antibodies, 139
Acellular vaccine
Pertussis, Filamentous haemagglutinin, 614
Pertussis, Universal childhood immunization, 1033
Bordetella pertussis, Detoxified pertussis toxin, 1027
Acetylated mannan
Newcastle disease virus, Infectious bursal disease virus, 551
Actinobacillus pleuropneumoniae
Recombinant, Dose-response, 512
Active hepatitis A vaccination
Immunogenicity, Safety, S132
Acute
Hepatitis A, Fulminant, 21
Adenohepatitis B
Recombinant, Human volunteers, 673
Adherence
Vibrio cholerae, Colonization, 1015
Adjuvant
Liposome, *N*-acetylmuramyl-L-alanyl-D-isoglutamine, 151
Bovine herpesvirus type 1, Interleukin-2, 226
Cytokines, Immunodeficiency, 427
Malaria, B-cell epitopes, 547
Tetanus toxoid, Microparticles, 714
Adjuvant effect
Inactivated influenza virus vaccine, Mouse recombinant interferon-γ, 238
Adjuvants
Low toxicity, Friend murine leukaemia, 353
Parainfluenza virus type 3, Antibody response, 412
IRIV, Hepatitis A vaccine, 915
Adverse reactions
Pertussis, Dose response 14
Aerosol administration
Inactivated influenza vaccine, Local IgA antibody, 506
Albanian immigrant population
Poliomyelitis, Cold chain, 853
Aluminium hydroxide
Influenza vaccine, Recombinant, 309
Animal models
Species-specific viruses, Retrovirus, 847
Anti-HAV response
Virus strain, Dose effect, 114
Anti-infectious protection
Propolis derivative, Tumour necrosis factor production, 817
Antibodies
Acellular pertussis vaccine, Potency testing, 139
Antibody persistence
Hepatitis A vaccine, Duration of protection, 129
Antibody prevalence
Hepatitis A, Disease trends, 59
Antibody response
Parainfluenza virus type 3, Adjuvants, 412
Malarial antigen, Small mammals, 540
Antigen
Ostertagia circumcincta, Cell-mediated immunity, 607
Antigen presentation
ISCOM, Palmitic acid, 597
Antigen processing
T cell-presented epitope, MHC molecules, 3
Antigen-antibody complexes
Postexposure treatment, Mouse anti-rabies monoclonal antibodies, 754
Antitoxin
Tetanus, Booster, 334
Aotus monkeys
Plasmodium falciparum, Blood stage antigens, 920
Arctic fox
Oral vaccination, Rabies, 305
Arenavirus
Attenuation, Recombinant, 89
Aro mutants
Salmonella typhi, Typhoid-tetanus vaccine, 53
AroA vaccines
Salmonella entertiidis PT4, Chickens, 247
AroD deletion
Shigella flexneri, Oral vaccination, 389
Escherichia coli–Shigella hybrid vaccine, Attenuation, 766
Assessment
Virus strain, Substrate, 99
Attenuated vaccine
Immune globulins, Inactivated vaccine, 10
Attenuation
Arenavirus, Recombinant, 89
Escherichia coli–Shigella hybrid vaccine, AroD deletion, 766
Aujeszky's disease vaccine
Dose, Maternal antibodies, 363
Autographa californica
Occlusion bodies, Influenza, 231
Autoimmune diseases
Synthetic vaccines, Infectious diseases,, 991
Auxotrophic mutants
Salmonella typhimurium, Oral vaccine, 61
Avian retroviral recombinant foreign envelope
Protection, Tumour formation, 375
Avipoxvirus
Recombinant, Mammals, 8

B subunit-whole cell vaccine
Cholera, Field trials, 146
B-cell eiptopes
Malaria, Adjuvant, 547
B-subunit-whole-cell
Cholera, Crossed immunoelectrophoresis, 591
BCG
Hepatitis B, Poliovirus, 319
Bacterial vaccines
Veterinary, Human, 977
Biostatistical analysis
EPI vaccines, Potency control, 157
Blood stage antigens
Plasmodium falciparum, Aotus monkeys, 920
Bluetongue virus
Virus-like particles, Sheep, 28
Bonnet monkeys
Poliovirus, Neurovirulence, 529
Booster
Hepatitis B vaccine, Low-dose, 33
Hepatitis A, Protection, 295
Tetanus, Antitoxin, 334
Bordetella pertussis
Pertactin, Recombinant, 43
Acellular vaccine, Detoxified pertussis toxin, 1027
Bovine herpesvirus type 1
Interleukin-2, Adjuvant, 226
Bovine papilloma virus
Epstein–Barr virus, Vector expression system, 777
Bunyaviridae
Vaccinia, Hantaan virus, 10
Burkitt's lymphoma
Epstein–Barr virus, Nasopharyngeal carcinoma, 563

CS peptide
RESA peptides, *Plasmodium falciparum*, 761
CVI
WHO, Children, 909
Camel orthopoxvirus
Camelpox, Vaccinia, 533
Camelpox
Camel orthopoxvirus, Vaccinia, 533
Canine distemper virus
Phocid distemper virus, ISCOMs, 435
Capsids
Porcine parvovirus, Recombinant baculovirus, 684
Capsular polysaccharide
Haemophilus influenzae type b immunity, Radioantigen-binding assay, 627
Cattle
Intradermal, *Escherichia coli*, 217
Foot and mouth disease vaccine, Potency testing, 699, 707
Cell clones
Virus mutants, Transfection, 36

Cell culture
Recombinant, Hepatitis A, 48
Cell-mediated immunity
Antigen, *Ostertagia circumcincta*, 607
Challenge
Shigella flexneri, *Macaca fascicularis*, 167
Chickens
Salmonella enteritidis PT4, AroA vaccines, 247
Childhood diseases
Immunization, United Kingdom, 491
Children
Malaria, Synthetic vaccine, 175
Influenza, Immune response, 221
Human immunodeficiency virus (HIV), Hepatitis B vaccine, 857
CVI, WHO, 909
Cholera
Experimental infection, Thai adults, 502
B-subunit-whole-cell, Crossed immunoelectrophoresis, 591
B subunit-whole cell vaccine, Field trials, 146
Cholera toxin B subunit
Immunochemistry, Influenza, 101
Cholera toxin protection in mice
Oral cholera vaccines, 735
Cholestasis
Hepatitis A, Clinical manifestation, 18
Clinical manifestation
Hepatitis A, Cholestasis, 18
Cold chain
Poliomyelitis, Albanian immigrant population, 853
Manufacturer, Temperature monitoring, 949
Colonization
Vibrio cholerae, Adherence, 1015
Combined immunization
Rabies, Typhoid fever, 299
Combined vaccine
Haemophilus influenzae type b, Injection site, 455
Combined vaccines
Infant immunization, HAV, 85
Conjugate vaccines
Meningococcus A, Meningococcus C, 691
Consistency
Hepatitis A vaccination, Immunogenicity, 500
Contraindications
Vaccination, Perceptions of medical practitioners, 742
Cost
Vaccine quality, EPI, 952
Cost-effectiveness analysis
Hepatitis A, Travellers, 88
Costs
Vaccination, EPI, 936
Cotton rats
Respiratory syncytial virus, Enhanced pulmonary histopathology, 475
Coverage
EPI, Future policies, 940
Creatine phosphokinase
Exercise, Hepatic injury, 43
Cross-protection
Tick-borne encephalitis virus, European and Far Eastern subtypes, 345
Crossed immunoelectrophoresis
Cholera, B-subunit-whole-cell, 591
Cytokines
Adjuvant, Immunodeficiency, 427
Cytotoxic T lymphocytes
Plasmodium yoelii, Recombinant pseudorabies virus, 578

Dedicated research team
AIDS, Pathogenesis, 1053
Delayed type hypersensitivity
Herpes simplex virus, T cells, 447
Detoxified pertussis toxin
Bordetella pertussis, Acellular vaccine, 1027
Developing countries
Vaccine supply, Quality control, 954
Discontinuity in research
Pertussis vaccines, Prematurity in scientific discovery, 643
Disease trends
Hepatitis A, Antibody prevalence, 59
Distribution
Epidemic, Endemic, 56
Dose
Aujeszky's disease vaccine, Maternal antibodies, 363
Dose effect
Virus strain, Anti-HAV response, 114
Dose response
Pertussis, Adverse reactions, 14
Dose-response
Actinobacillus pleuropneumoniae, Recombinant, 512
Duration of protection
Hepatitis A vaccine, Antibody persistence, 129

ELISA
Newcastle disease virus, Haemagglutination inhibition, 164
EPI
Vaccination, Costs, 936
Coverage, Future policies, 940
Vaccine quality, Cost, 952
EPI vaccines
Biostatistical analysis, Potency control, 157
Early immune response
Hepatitis A vaccination, Immunization schedules, 126
Efficacy
Hepatitis A, Thailand, 159
Endemic
Epidemic, Distribution, 56
Enhanced pulmonary histopathology
Respiratory syncytial virus, Cotton rats, 475
Enterovirus
Heparnavirus, Hepatovirus, S24
Epidemic
Endemic, Distribution, S56
Hepatitis A, Shellfish, 67
Epidemiology
Hepatitis A, Mediterranean area, 63
Epitope
Polymerase chain reaction, Simian hepatitis A virus, 40
Epstein–Barr virus
Burkitt's lymphoma, Nasopharyngeal carcinoma, 563
Bovine papilloma virus, Vector expression system, 777
Escherichia coli
Intradermal, Cattle, 217
***Escherichia coli–Shigella* hybrid vaccine**
AroD deletion, Attenuation, 766
European and Far Eastern subtypes
Tick-borne encephalitis virus, Cross-protection, 345
European vaccine manufacturers
Supply, Price, 893
Evaluation
Measles, Seroconversion, 49
Exercise
Creatine phosphokinase, Hepatic injury, 43
Experimental infection
Cholera, Thai adults, 502

FMD vaccines
Production and challenge viruses, VP1 RNA sequences comparison, 731
Feline immunodeficiency
Human immunodeficiency virus, Simian immunodeficiency virus, 677
Field trial
Plasmodium falciparum, *Plasmodium vivax*, 179
Hepatitis A, Military, 156
Field trials
Cholera, B subunit-whole cell vaccine, 146
Filamentous haemagglutinin
Pertussis, Acellular vaccine, 614
Flavivirus
Japanese encephalitis, Monoclonal antibodies, 329
Foot and mouth disease
Immunization policy, Recombinant DNA technology, 1022
Foot and mouth disease vaccine
Cattle, Potency testing, 699, 707
Formalin-inactivated vaccine
Respiratory syncytial virus, Purified proteins, 113
Friend murine leukaemia
Adjuvants, Low toxicity, 353
Fulminant
Hepatitis A, Acute, 21
Future policies
EPI, Coverage, 940

Gardia lamblia
Oral-systemic, Trophozoites, 21
Glycoalkaloid
ISCOM, Saponin, 572

HAV
Infant immunization, Combined vaccines, 85
Structural and non-structural antigen, *In vitro* transcription/translation, S106
HAV vaccine
Immune globulin, Interference, S138
HIV
AIDS, Vaccine development, 1039
HM175 strain
Hepatitis A virus, Reactogenicity, 110
Hepatitis A, Health professionals, 119
Haemagglutination inhibition
Newcastle disease virus, ELISA, 164
Haemagglutinin
Influenza, Salmonella, 405
Haemagglutinin mutants

Influenza vaccine, Virus quasispecies, 603
***Haemophilus influenzae* type b**
Combined vaccine, Injection site, 455
***Haemophilus influenzae* type b immunity**
Capsular polysaccharide, Radioantigen-binding assay, 627
Haemorrhagic fever with renal syndrome
Inactivated vaccine, Human trial, 214
Hantaan virus
Vaccinia, Bunyaviridae, 10
Health service policy
Non-government organizations, Vaccine delivery systems, 958
Health professionals
Hepatitis A, HM175 strain, 119
Heat stability
Recombinant DNA, Hepatitis B, 366
Heparnavirus
Enterovirus, Hepatovirus, 24
Hepatic injury
Exercise, Creatine phosphokinase, 43
Hepatitis A
Acute, Fulminant, S21
Antibody prevalence, Disease trends, S59
Clinical manifestation, Cholestasis, S18
Cost-effectiveness analysis, Travellers, S88
Efficacy, Thailand, S159
Epidemiology, Mediterranean area, S63
Field trial, Military, S156
HM175 strain, Health professionals, S119
Immune globulin, Traveller, S73
Immunoassay, Neutralization test, S102
Immunogenicity, Side effects, S152
Lyophilized, Inactivated, 323
Occupational risk, Medical personnel, S82
One-dose regimen, Liposomes, 737
Peacekeeping operations, Military, S80
Protection, Booster, 295
Recombinant, Cell culture, 48
Shellfish, Epidemic, S67
Travellers, Short-term schedule, S124
Viral hepatitis, Liver, S135
Viral hepatitis, WHO, S93
Hepatitis A vaccination
Consistency, Immunogenicity, 500
Immunization schedules, Early immune response, S126
Hepatitis A vaccine
Adjuvants, IRIV, 915
Antibody persistence, Duration of protection, S129
Reactogenicity, Immunogenicity, 160
Hepatitis A vaccines
Reactogenicity, Parotid antibody response, S121
Hepatitis A virus
HM175 strain, Reactogenicity, S110
Host range, Non-human primates, S27
Immunoprophylaxis, Immunoglobulin, 148
Neutralizing antibody, Immunoglobulin, S45
Picornavirus, Protein synthesis, 32
Hepatitis B
BCG, Poliovirus, 319
Heat stability, Recombinant DNA, 366
Non-responders, Neonates, 69
Plasma-derived, Yeast-derived, 301
Recombinant DNA technology, Viral hepatitis, 900
Recombinant hepatitis B surface antigen, Immune response, 617
Recombinant, Immunogenicity, 439
Recombinant, Plasma-derived, 379, 740
Vaccine, Intravenous drug addicts, 798
Viral antigen, Synthetic peptide, 814
Hepatitis B surface antigen
Synthetic peptide, Quaternary epitope, 204
Hepatitis B vaccine
Human immunodeficiency virus (HIV), Children, 857
Low-dose, Booster, 33
Hepatovirus
Enterovirus, Heparnavirus, 24
Herd immunity
Vaccination programmes, Transmission dynamics, 928
Herpes simplex virus
Delayed type hypersensitivity, T cells, 447
Recombinant antigen, Liposomes, 209
Host range
Hepatitis A virus, Non-human primates, 27
Human
Bacterial vaccines, Veterinary, 977
Human Immunodeficiency Virus type 1
ISCOM, Virus neutralizing antibody, 585
Human diploid cell vaccine
Rabies, ISCOM, 192
Human immunodeficiency virus
Hepatitis B vaccine, Children, 857
Lymphocyte proliferation, Recombinant gp160, 383
Simian immunodeficiency virus, Feline immunodeficiency, 677
Human trial
Haemorrhagic fever with renal syndrome, Inactivated vaccine, 214
Human volunteers
Adenohepatitis B, Recombinant, 673
Humans
Shigella flexneri, Oral vaccination, 395

IPV
Poliomyelitis, OPV, 904
IRIV
Adjuvants, Hepatitis A vaccine, 915
ISCOM
Antigen peresentation, Palmitic acid, 597
Human Immunodeficiency Virus type 1, Virus neutralizing antibody, 585
Rabies, Human diploid cell vaccine, 192
Saponin, Glycoalkaloid, 572
ISCOMs
Phocid distemper virus, Canine distemper virus, 435
ISCOMs vaccine
Respiratory syncytial virus, Intramuscular, 107
Immune globulin
HAV vaccine, Interference, 138
Hepatitis A, Traveller, S73
immune globulins
Inactivated vaccine, Attenuated vaccine, S10
Immune response
Hepatitis B, Recombinant hepatitis B surface antigen, 617
Influenza, Children, 221
Immunization
Rabies virus, Rabies vaccines, 896
United Kingdom, Childhood diseases, 491
Immunization in travellers
Incidence rate, Seroprevalence, S69
Immunization policy
Foot-and-mouth disease, Recombinant DNA technology, 1022
Immunization schedules
Hepatitis A vaccination, Early immune response, 126
Immunoassay
Hepatitis A, Neutralization test, 102
Immunochemistry
Cholera toxin B subunit, Influenza, 101
Immunocompromised subjects
Varicella, Zoster, 1007
Immunodeficiency
Cytokines, Adjuvant, 427
Immunogenicity
Active hepatitis A vaccination, Safety, 132
Hepatitis A, Side effects, 152
Hepatitis A vaccination, Consistency, 500
Hepatitis B, Recombinant, 439
Japanese encephalitis, Vaccine, 861
Oral cholera vaccine, Safety, 130
Reactogenicity, Hepatitis A vaccine, 160
Tick-borne encephalitis, Side effects, 145
Vaccine combination, Reactogenicity, 142
Viral antigen, Synthetic peptide, 814
Immunoglobulin
Hepatitis A virus, Neutralizing antibody, 45
Immunoprophylaxis, Hepatitis A virus, 148
Immunoglobulin A
Intestinal immunity, *Salmonella typhi*, 802
Immunoglobulin anti-HAV
Prodrome, Symptoms, 15
Immunological adjuvants
Liposomes, Influenza virus antigens, 747
Immunoprophylaxis
Hepatitis A virus, Immunoglobulin, S148
Immunosuppression
Salmonella enterica, Live vaccine, 243
***In vitro* transcription/translation**
HAV, Structural and non-structural antigen, 106
Inactivated
Hepatitis A, Lyophilized, 323

Inactivated influenza vaccine
Local IgA antibody, Aerosol administration, 506
Inactivated influenza virus vaccine
Adjuvant effect, Mouse recombinant interferon-γ, 238
Inactivated poliovirus vaccine
Intradermal, Infants, 135
Inactivated vaccine
Haemorrhagic fever with renal syndrome, Human trial, 214
Immune globulins, Attenuated vaccine, 10
Incidence rate
Immunization in travellers, Seroprevalence, 69
Infant immunization
Combined vaccines, HAV, S85
Infants
Inactivated poliovirus vaccine, Intradermal, 135
Infectious bronchitis virus
Nucleocapsid, Recombinant DNA, 119
Infectious bursal disease virus
Acetylated mannan, Newcastle disease virus, 551
Infectious diseases
Synthetic vaccines, Autoimmune diseases, 991
Infectious hepatitis
Military, Jaundice, 75
Influenza
Autographa californica, Occlusion bodies, 231
Children, Immune response, 221
Cholera toxin B subunit, Immunochemistry, 101
Haemagglutinin, Salmonella, 405
Liposomal avridine, Turkeys, 623
Influenza B
Serological match, Pre-existing antibody, 631
Influenza vaccine
Haemagglutinin mutants, Virus quasispecies, 603
Recombinant, Aluminium hydroxide, 309
Influenza virus
MDP-virosome vaccine, Leucocytosis, 663
Influenza virus antigens
Liposomes, Immunological adjuvants, 747
Injection site
Haemophilus influenzae type b, Combined vaccine, 455
Interference
HAV vaccine, Immune globulin, 138
Interleukin-2
Bovine herpesvirus type 1, Adjuvant, 226
Intestinal immunity
Salmonella typhi, Immunoglobulin A, 802
Intrabursal
Mycoplasma gallisepticum, Intracoelomic, 655
Intracoelomic
Mycoplasma gallisepticum, Intrabursal, 655
Intradermal
Escherichia coli, Cattle, 217
Inactivated poliovirus vaccine, Infants, 135
Rabies, Intramuscular, 125
Intramuscular
Rabies, Intradermal, 125
Respiratory syncytial virus, ISCOMs vaccine, 107
Intransaal
Polysaccharide, Liposome, 461
Intravenous drug addicts
Hepatitis B, Vaccine, 798

Japanese encephalitis
Flavivirus, Monoclonal antibodies, 329
Immunogenicity, Vaccine, 861
Jaundice
Military, Infectious hepatitis, 75

Laboratory rodents
Tissue culture vaccine against hepatitis A, Vaccination schedules, 828
Leucocytes
Respiratory syncytial virus, Pathogenesis, 519
Leucocytosis
MDP-virosome vaccine, Influenza virus, 663
Liposomal avridine
Influenza, Turkeys, 623
Liposome
Intranasal, Polysaccharide, 461
N-acetylmuramyl-L-alanyl-D-isoglutamine, Adjuvant, 151
Liposomes
Hepatitis A, One-dose regimen, 737
Herpes simplex virus, Recombinant antigen, 209
Influenza virus antigens, Immunological adjuvants, 747
Live
Staphylococus aureus, Mastitis, 359
Live vaccine
Salmonella enterica, Immunosuppression, 243
Liver
Hepatitis A, Viral hepatitis, 135
Local IgA antibody
Inactivated influenza vaccine, Aerosol administration, 506
Low toxicity
Adjuvants, Friend murine leukaemia, 353
Low-dose
Hepatitis B vaccine, Booster, 33
Lymphocyte proliferation
Human immunodeficiency virus, Recombinant gp160, 383
Lymphocytes
Muscosal, Secretory IgA, 75
Lyophilized
Hepatitis A, Inactivated, 323

MDP-virosome vaccine
Influenza virus, Leucocytosis, 663
MHC molecules
Antigen processing, T cell-presented epitope, 3
Macaca fascicularis
Shigella flexneri, Challenge, 167
Malaria
Adjuvant, B-cell epitopes, 547
Synthetic vaccine, Children, 175
Malarial antigen
Antibody response, Small mammals, 540
Mammals
Avipoxvirus, Recombinant, 8
Manufacturer
Cold chain, Temperature monitoring, 949
Mastitis
Staphylococus aureus, Live, 359
Maternal antibodies
Aujeszky's disease vaccine, Dose, 363
Measles
Seroconversion, Evaluation, 49
Medical personnel
Hepatitis A, Occupational risk, 82
Mediterranean area
Hepatitis A, Epidemiology, 63
Meningococcus A
Meningococcus C, Conjugate vaccines, 691
Meningococcus C
Meningococcus A, Conjugate vaccines, 691
Metastasis
Muramyl dipeptide, Tumour immunity, 792
Mice
Salmonelkla typhi, Strain-specific porins, 811
Microparticles
Tetanus toxoid, Adjuvant, 714
Military
Hepatitis A, Field trial, 156
Hepatitis A, Peacekeeping operations, 80
Infectious hepatitis, Jaundice, S75
Monoclonal antibodies
Japanese encephalitis, Flavivirus, 329
Monocomponent
Pertussis, Two-component, 142
Mouse anti-rabies monoclonal antibodies
Postexposure treatment, Antigen–antibody complexes, 754
Mouse recombinant interferon-γ
Adjuvant effect, Inactivated influenza virus vaccine, 238
Mumps
Nasal antibody, 824
Muramyl dipeptide
Tumour immunity, Metastasis, 792
Muscosal
Secretory IgA, Lymphocytes, 75
Mycoplasma gallisepticum
Intracoelomic, Intrabursal, 655

***N*-acetylmuramyl-L-alanyl-D-isoglutamine**
Liposome, Adjuvant, 151
Nasal antibody
Mumps, 824
Nasopharyngeal carcinoma
Epstein–Barr virus, Burkitt's lymphoma, 563
Neisseria meningitidis
Outer membrane proteins, T-cell epitopes, 159
Neonates
Hepatitis B, Non-responders, 69
Neurovirulence
Poliovirus, Bonnet monkeys, 529
Poliovirus vaccine, Test evaluation, 469

Neutralization test
Hepatitis A, Immunoassay, 102
Neutralizing antibody
Hepatitis A virus, Immunoglobulin, 45
Newcastle disease virus
Acetylated mannan, Infectious bursal disease virus, 551
ELISA, Haemagglutination inhibition, 164
Non-government organizations
Health service policy, Vaccine delivery systems, 958
Non-human primates
Hepatitis A virus, Host range, 27
Non-responders
Hepatitis B, Neonates, 69
Non-specific host stimulation
Synthetic immunoadjuvants, Vaccine adjuvants, 166
Nucleocapsid
Infectious bronchitis virus, Recombinant DNA, 119

OPV
Poliomyelitis, IPV, 904
Occlusion bodies
Autographa californica, Influenza, 231
Occupational risk
Hepatitis A, Medical personnel, 82
One-dose regimen
Hepatitis A, Liposomes, 737
Oral cholera vaccine
Safety, Immunogenicity, 130
Oral cholera vaccines
Cholera toxin protection in mice, 735
Oral polio vaccine
Working standard, Virus titre, 423
Oral vaccination
Arctic fox, Rabies, 305
Rabies, Pathogenicity, 524
Shigella flexneri, AroD deletion, 389
Shigella flexneri, Humans, 395
Oral vaccine
Salmonella typhimurium, Auxotrophic mutants, 61
Oral-systemic
Giardia lamblia, Trophozoites, 21
Ostertagia circumcincta
Antigen, Cell-mediated immunity, 607
Outer membrane proteins
Neisseria meningitidis, T-cell epitopes, 159

Palmitic acid
ISCOM, Antigen presentation, 597
Parainfluenza virus type, 3
Adjuvants, Antibody response, 412
Parotid antibody response
Hepatitis A vaccines, Reactogenicity, 121
Pathogenesis
AIDS, Dedicated research team, 1053
Respiratory syncytial virus, Leucocytes, 519
Pathogenicity
Rabies, Oral vaccination, 524
Peacekeeping operations
Hepatitis A, Military, 80
Peptide carrier
VP6 particles, Rotavirus, 783
Perceptions of medical practitioners
Contraindications, Vaccination, 742
Pertactin
Bordetella pertussis, Recombinant, 43
Pertussis
Acellular, A protomer, 341
Acellular vaccine, Filamentous haemagglutinin, 614
Acellular vaccine, Universal childhood immunization, 1033
Adverse reactions, Dose response, 14
Monocomponent, Two-component, 142
Pertussis vaccines
Discontinuity in research, Prematurity in scientific discovery, 643
Phocid distemper virus
Canine distemper virus, ISCOMs, 435
Picornavirus
Hepatitis A virus, Protein synthesis, S32
Plasma-derived
Hepatitis B, Yeast-derived, 301
Hepatitis B, Recombinant, 379, 740
Plasmodium falciparum
Aotus monkeys, Blood stage antigens, 920
Field trial, *Plasmodium vivax*, 179
RESA peptides, CS peptide, 761
***Plasmodium falciparum* malaria vaccine**
Recombinant vaccine, Sporozoite, 841
Plasmodium vivax
Plasmodium falciparum, Field trial, 179
Plasmodium yoelii
Recombinant pseudorabies virus, Cytotoxic T lymphocytes, 578
Poliomyelitis
Albanian immigrant population, Cold chain, 853
OPV, IPV, 904
Virus-induced autoimmunity, Systemic lupus erythematosus, 98
Poliovirus
Hepatitis B, BCG, 319
Neurovirulence, Bonnet monkeys, 529
Poliovirus vaccine
Neurovirulence, Test evaluation, 469
Polymerase chain reaction
Epitope, Simian hepatitis A virus, S40
Polysaccharide
Intranasal, Liposome, 461
Polysaccharide protein conjugate vaccine
Streptococcus pneumoniae, Saccharide, 833
Porcine parvovirus
Capsids, Recombinant baculovirus, 684
Postexposure treatment
Mouse anti-rabies monoclonal antibodies, Antigen–antibody complexes, 754
Postvaccination complications
Vaccinia, Recombinant vaccinia vaccine, 96
Potency control
Biostatistical analysis, EPI vaccines, 157
Potency testing
Acellular pertussis vaccine, Antibodies, 139
Foot and mouth disease vaccine, Cattle, 699, 707
Pre-existing antibody
Influenza B, Serological match, 631
Prematurity in scientific discovery
Discontinuity in research, Pertussis vaccines, 643
Price
European vaccine manufacturers, Supply, 893
Primates
Rabies, Vaccinia recombinant virus, 368
Prodrome
Symptoms, Immunoglobulin anti-HAV, S15
Production and challenge viruses
FMD vaccines, VP1 RNA sequences comparison, 731
Propolis derivative
Anti-infectious protection, Tumour necrosis factor production, 817
Protection
Avian retroviral recombinant foreign envelope, Tumour formation, 375
Hepatitis A, Booster, 295
Protein synthesis
Picornavirus, Hepatitis A virus, 32
Purified proteins
Respiratory syncytial virus, Formalin-inactivated vaccine, 113

Quality
Supply, Transfer of technology, 955
Quality control
Vaccine supply, Developing Countries, 954
Quaternary epitope
Synthetic peptide, Hepatitis B surface antigen, 204

RESA peptides
CS peptide, *Plasmodium falciparum*, 761
Rabies
Intramuscular, Intradermal, 125
ISCOM, Human diploid cell vaccine, 192
Oral vaccination, Arctic fox, 305
Oral vaccination, Pathogenicity, 524
Typhoid fever, Combine immunization, 299
Vaccinia recombinant virus, Primates, 368
Rabies vaccines
Rabies virus, Immunization, 896
Rabies virus
Rabies vaccines, Immunization, 896
Radioantigen-binding assay
Haemophilus influenzae type b immunity, Capsular polysaccharide, 627
Reactogenicity
Hepatitis A vaccines, Parotid antibody response, 121
Hepatitis A virus, HM175 strain, 110
Immunogenicity, Hepatitis A vaccine, S160
Vaccine combination, Immunogenicity, 142
Recombinant
Actinobacillus pleuropneumoniae, Dose-response, 512
Adenohepatitis B, Human volunteers, 673

Arenavirus, Attenuation, 89
Hepatitis A, Cell culture, S48
Hepatitis B, Immunogenicity, 439
Hepatitis B, Plasma-derived, 379, 740
Influenza vaccine, Aluminium hydroxide, 309
Pertactin, *Bordetella pertussis*, 43
Vaccinia, Rotavirus, 185
Recombinant DNA
Heat stability, Hepatitis B, 366
Infectious bronchitis virus, Nucleocapsid, 119
Recombinant DNA technology
Foot-and-mouth disease, Immunization policy, 1022
Hepatitis B, Viral hepatitis, 900
Recombinant antigen
Herpes simplex virus, Liposomes, 209
Recombinant baculovirus
Porcine parvovirus, Capsids, 684
Recombinant gp160
Lymphocyte proliferation, Human immunodeficiency virus, 383
Recombinant hepatitis B surface antigen
Hepatitis B, Immune response, 617
Recombinant pseudorabies virus
Plasmodium yoelii, Cytotoxic T lymphocytes, 578
Recombinant vaccine
Plasmodium falciparum malaria vaccine, Sporozoite, 841
Recombinant vaccinia vaccine
Vaccinia, Postvaccination complications, 96
Respiratory syncytial virus
Enhanced pulmonary histopathology, Cotton rats, 475
Formalin-inactivated vaccine, Purified proteins, 113
ISCOMs vaccine, Intramuscular, 107
Pathogenesis, Leucocytes, 519
Retrovirus
Species-specific viruses, Animal models, 847
Rotavirus
Peptide carrier, VP6 particles, 783
Recombinant, Vaccinia, 185

SIV vaccine
AIDS animal model, 873
Saccharide
Streptococcus pneumonia,e Polysaccharide protein conjugate vaccine, 833
Safety
Active hepatitis A vaccination, Immunogenicity, 132
Oral cholera vaccine, Immunogenicity, 130
Salmonella
Influenza, Haemagglutinin, 405
Salmonella enterica
Live vaccine, Immunosuppression, 243
***Salmonella enteritidis* PT4**
Chickens, AroA vaccines, 247
Salmonella typhi
Aro mutants, Typhoid-tetanus vaccine, 53
Intestinal immunity, Immunoglobulin A, 802
Mice, Strain-specific porins, 811
Salmonella typhimurium
Oral vaccine, Auxotrophic mutants, 61
Saponin
ISCOM, Glycoalkaloid, 572
Secretory IgA
Muscosal, Lymphocytes, 75
Seroconversion
Measles, Evaluation, 49
Serological match
Influenza B, Pre-existing antibody, 631
Seroprevalence
Immunization in travellers, Incidence rate, 69
Sheep
Bluetongue virus, Virus-like particles, 28
Shellfish
Hepatitis A, Epidemic, 67
Shigella flexneri
AroD deletion, Oral vaccination, 389
Macaca fascicularis, Challenge, 167
Oral vaccination, Humans, 395
Short-term schedule
Hepatitis A, Travellers, 124
Side effects
Hepatitis A, Immunogenicity, 152
Tick-borne encephalitis, Immunogenicity, 145
Simian hepatitis A virus
Polymerase chain reaction, Epitope, 40
Simian immunodeficiency virus
Human immunodeficiency virus, Feline immunodeficiency, 677
Small mammals
Antibody response, Malarial antigen, 540
Species-specific viruses
Retrovirus, Animal models, 847
Sporozoite
Plasmodium falciparum malaria vaccine, Recombinant vaccine, 841
Staphylococus aureus
Live, Mastitis, 359
Strain-specific porins
Salmonella typhi, Mice, 811
Streptococcus pneumoniae
Polysaccharide protein conjugate vaccine, Saccharide, 833
Structural and non-structural antigen
HAV, *In vitro* transcription/ translation, 106
Substrate
Virus strain, Assessment, 99
Supply
European vaccine manufacturers, Price, 893
Quality, Transfer of technology, 955
Symptoms
Prodrome, Immunoglobulin anti-HAV, 15
Synthetic immunoadjuvants
Vaccine adjuvants, Non-specific host stimulation, 1000
Synthetic peptide
Hepatitis B surface antigen, Quaternary epitope, 204
Viral antigen, Hepatitis B, 814
Synthetic vaccine
Malaria, Children, 175
Synthetic vaccines
Autoimmune diseases, Infectious diseases, 991
Systemic lupus erythematosus
Virus-induced autoimmunity, Poliomyelitis, 98

T cell-presented epitope
Antigen processing, MHC molecules, 3
T cells
Herpes simplex virus, Delayed type hypersensitivity, 447
T-cell epitopes
Neisseria meningitidis, Outer membrane proteins, 159
Temperature monitoring
Manufacturer, Cold chain, 949
Temperature sensitivity
Yellow fever virus vaccines, 652
Test evaluation
Poliovirus vaccine, Neurovirulence, 469
Tetanus
Booster, Antitoxin, 334
Tetanus toxoid
Microparticles, Adjuvant, 714
Thai adults
Cholera, Experimental infection, 502
Thailand
Hepatitis A, Efficacy, 159
Tick-borne encephalitis
Immunogenicity, Side effects, 145
Tick-borne encephalitis virus
European and Far Eastern subtypes, Cross-protection, 345
Tissue culture vaccine against hepatitis A
Laboratory rodents, Vaccination schedules, 828
Transfection
Virus mutants, Cell clones, 36
Transfer of technology
Supply, Quality, 955
Transmission dynamics
Vaccination programmes, Herd immunity, 928
Traveller
Hepatitis A, Immune globulin, 73
Travellers
Hepatitis A, Cost-effectiveness analysis, 88
Hepatitis A, Short-term schedule, 124
Trophozoites
Giardia lamblia, Oral-systemic, 21
Tumour formation
Avian retroviral recombinant foreign envelope, Protection, 375
Tumour immunity
Muramyl dipeptide, Metastasis, 792
Tumour necrosis factor production
Propolis derivative, Anti-infectious protection, 817
Turkeys
Influenza, Liposomal avridine, 623
Two-component
Pertussis, Monocomponent, 142
Typhoid fever
Rabies, Combine immunization, 299
Typhoid-tetanus vaccine
Salmonella typhi, Aro mutants, 53

United Kingdom
Immunization, Childhood diseases, 491

Universal childhood immunization
Pertussis, Acellular vaccine, 1027

VP1 RNA sequences comparison
FMD vaccines, Production and challenge viruses, 731
VP6 particles
Peptide carrier, Rotavirus, 783
Vaccination
Contraindications, Perceptions of medical practitioners, 742
Costs, EPI, 936
Vaccination programmes
Herd immunity, Transmission dynamics, 928
Vaccination schedules
Tissue culture vaccine against hepatitis A, Laboratory rodents, 828
Vaccine
Hepatitis B, Intravenous drug addicts, 798
Immunogenicity, Japanese encephalitis, 861
Vaccine adjuvants
Synthetic immunoadjuvants, Non-specific host stimulation, 166
Vaccine combination
Reactogenicity, Immunogenicity, S142
Vaccine delivery systems
Non-government organizations, Health service policy, 958
Vaccine development
AIDS, HIV, 1039
Vaccine quality
EPI, Cost, 952
Vaccine supply
Developing countries, Quality control, 954
Vaccinia
Camel orthopoxvirus, Camelpox, 533
Bunyaviridae, Hantaan virus, 10
Postvaccination complications, Recombinant vaccinia vaccine, 96
Recombinant, Rotavirus, 185
Vaccinia recombinant virus
Rabies, Primates, 368
Varicella
Zoster, Immunocompromised subjects, 1007
Vector expression system
Bovine papilloma virus, Epstein–Barr virus, 777
Veterinary
Bacterial vaccines, Human
Vibrio cholerae
Adherence, Colonization, 1015
Viral antigen
Synthetic peptide, Hepatitis B, 814
Viral hepatitis
Hepatitis A, Liver, 135
Hepatitis A, WHO, 93
Hepatitis B, Recombinant DNA technology, 900
Virus mutants
Cell clones, Transfection, S36
Virus neutralizing antibody
ISCOM, Human Immunodeficiency Virus Type 1, 585
Virus quasispecies
Influenza vaccine, Haemagglutinin mutants, 603
Virus strain
Substrate, Assessment, S99
Dose effect, Anti-HAV response, S114
Virus titre
Oral polio vaccine, Working standard, 423
Virus-induced autoimmunity
Poliomyelitis, Systemic lupus erythematosus, 98
Virus-like particles
Bluetongue virus, Sheep, 28
WHO
CVI, Children, 909
Hepatitis A, Viral hepatitis, 93
Working standard
Oral polio vaccine, Virus titre, 423

Yeast-derived
Hepatitis B, Plasma-derived, 301
Yellow fever virus vaccines
Temperature sensitivity, 652
Zoster
Varicella, Immunocompromised subjects, 1007

Book reviews

A Practical Guide to Monoclonal Antibodies
A.M. Campbell, 71
Animal Cell Bioreactors
H. Leung, 487
Clinical Immunology
M. Browning, 639
Developments in Biological Standardisation. Volume 72: Progress in Animal Retroviruses
R. Thompson, 487
New Generation Vaccines
A.C. Wardlaw, 70

Conference report

WHO-NIH Meeting on Host Cell Selection of Influenza Virus Variants, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK, 13–14 November 1991
J.M. Katz, J.S. Robertson, 723